TIMP-1 Activates a Unique Cardiac Stem Cell Population, CD63+ve/C-KIT+ve, Thereby Enhancing Cardiac Differentiation, and Protects the Heart From Adverse Cardiac Remodeling Following Myocardial Infarction by Abdelli, Latifa
University of Central Florida 
STARS 
Electronic Theses and Dissertations, 2004-2019 
2015 
TIMP-1 Activates a Unique Cardiac Stem Cell Population, 
CD63+ve/C-KIT+ve, Thereby Enhancing Cardiac Differentiation, 
and Protects the Heart From Adverse Cardiac Remodeling 
Following Myocardial Infarction 
Latifa Abdelli 
University of Central Florida 
 Part of the Medical Sciences Commons 
Find similar works at: https://stars.library.ucf.edu/etd 
University of Central Florida Libraries http://library.ucf.edu 
This Doctoral Dissertation (Open Access) is brought to you for free and open access by STARS. It has been accepted 
for inclusion in Electronic Theses and Dissertations, 2004-2019 by an authorized administrator of STARS. For more 
information, please contact STARS@ucf.edu. 
STARS Citation 
Abdelli, Latifa, "TIMP-1 Activates a Unique Cardiac Stem Cell Population, CD63+ve/C-KIT+ve, Thereby 
Enhancing Cardiac Differentiation, and Protects the Heart From Adverse Cardiac Remodeling Following 
Myocardial Infarction" (2015). Electronic Theses and Dissertations, 2004-2019. 1198. 
https://stars.library.ucf.edu/etd/1198 
TIMP-1 ACTIVATES A UNIQUE CARDIAC STEM CELL POPULATION, CD63+ve/C-
KIT+ve, THEREBY ENHANCING CARDIAC DIFFERENTIATION, AND PROTECTS THE 
HEART FROM ADVERSE CARDIAC REMODELING FOLLOWING MYOCARDIAL 
INFARCTION 
 
 
 
by 
 
 
 
 
 
 
LATIFA S. ABDELLI 
B.S. Université des Sciences et Technologies Houari Boumediene. Algiers, 2006 
M.S. University of Central Florida, 2014 
 
 
 
 
 
 
 
A dissertation submitted in partial fulfillment of the requirements 
for the degree of Doctor of Philosophy 
in the Burnett School of Biomedical Sciences 
in the College of Medicine 
at the University of Central Florida 
Orlando, Florida 
 
 
 
 
 
 
 
 
Summer Term 
2015 
 
 
 
 
Major Professor: Dinender K. Singla  
ii 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© 2015 Latifa S. Abdelli 
  
iii 
ABSTRACT 
We previously demonstrated that embryonic stem (ES) cells over-expressing 
tissue inhibitor of metalloproteinase-1 (TIMP-1) have increased potential to engraft and 
differentiate into cardiac myocytes following transplantation into the infarcted heart. 
However, the ability of TIMP-1 to activate endogenous stem cells and enhance their 
differentiation into cardiac regenerative cell types is still unknown. We postulate that 
TIMP-1 may additionally activate a stem cell population that enhances cardiac cell type 
differentiation in the infarcted myocardium. To prove this hypothesis, we isolated c-kit+ve 
cells from four weeks old C57BL/6 mice and cultured them in vitro in presence of ES 
conditioned media (ESCM), ES-TIMP-1-CM or TIMP-1. Our immunostaining data 
validate the existence of a novel CD63+ve/c-kit+ve cells. When treated with TIMP-1, these 
cells showed significantly (p<0.05) increased proliferation and differentiation into cardiac 
myocytes, vascular smooth muscle cells, and endothelial cells. Western blot analysis 
revealed significantly (p<0.05) increased expression of CD63, phosphorylated and total 
β-catenin proteins. Furthermore, our RT-PCR data showed increased cardiac gene 
expression (GATA-4, Mef2C, and Nkx-2.5) when compared to ESCM and control cells. 
Based on the in vitro findings, we investigated the effect of intramyocardial delivery of 
TIMP-1 on endogenous CD63+ve/c-kit+ve cells following myocardial infarction (MI). 
C57BL/6 and TIMP-1 KO mice underwent coronary artery ligation followed by 
intramyocardial delivery of 20µl of culture media (CC), ESCM, ES-TIMP-1-CM or TIMP-
1. Subsequent immunohistochemistry analysis demonstrated the presence of a 
CD63+ve/c-kit+ve cell population within the peri-infarct area and confirmed intramyocardial 
delivery of ES-TIMP-1-CM or TIMP-1 significantly (p<0.05) enhanced their proliferation. 
iv 
Percentage of CD63+ve/c-kit+ve cells was significantly (p<0.05) lower in TIMP-1 KO mice 
compared to C57BL/6 animals. RT-PCR analysis revealed TIMP-1 KO animals 
expressed significantly less CD63 and TIMP-1 mRNAs compared to C57BL/6 mice. 
Activated CD63+ve/c-kit+ve cells were also able to differentiate into major cardiac cell 
types as previously shown in vitro. The differentiation potential of these cells was 
however higher in C57BL/6 mice compared to TIMP-1 KO mice. We also demonstrate 
that CD63+ve/c-kit+ve cells differentiation is regulated by CD63/β-catenin pathway in vivo. 
Additionally, we provide evidence that TIMP-1 protects the heart from adverse cardiac 
remodeling through inhibition of cardiac apoptosis and fibrosis leading to significantly 
(p<0.05) improved contractile function. Collectively, our data show TIMP-1 plays a dual 
protective role in the MI heart. It activates a unique stem cell population, CD63+ve/c-
kit+ve, which proliferates and differentiates into functional myocytes, smooth muscle cells 
and endothelial cells mediated through CD63/β-catenin pathway. TIMP-1 also protects 
the heart from adverse cardiac remodeling. Increased cardiac regeneration and 
inhibition of adverse cardiac remodeling consequently lead to restored cardiac function.    
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CHAPTER ONE: INTRODUCTION  
MI Prevalence and Epidemiology 
Myocardial infarction (MI) is a major health threat in the United States and other 
western countries. According to the American Heart Association (AHA) statistics for 
2014, more than 620,000 Americans will be hospitalized for an MI or coronary heart 
disease (CHD) and ~295,000 will have a recurrent attack. In terms of mortality rate, 
approximately every 34 seconds, 1 American has an MI, and approximately every 2 
minutes, an American will die of one (30). The incidence of MI is dependent on 
predisposing risk factors including: hypertension, diabetes mellitus, tobacco use, 
hyperlipidemia and family history of CHD (30). Any risk factor, if present, doubles the 
relative risk of developing atherosclerotic coronary artery disease. Currently used 
medications have significantly improved patients quality of life; however, these therapies 
are unable to prevent future episodes of MI, and mortality rate is still at record high (30).  
Therefore, finding alternative therapies with better short-term and long-term outcomes 
for MI patients is still at the forefront of medical research. 
Myocardial Infarction Pathophysiology  
Atherosclerotic plaque rupture in the main arteries of the left ventricle blocks 
blood and nutrient supply to the myocardium, leading to ischemia and MI (6; 32). 
Prolonged ischemia results in myocardial remodeling, which includes cardiac cell loss, 
generation of fibrotic scar tissue, cardiac myocyte hypertrophy and left ventricular 
dilation (2-4; 6). Necrosis and apoptosis are distinct forms of cell death, both occurring 
in ischemic heart, although in the first 24 h following infarction, apoptosis is the main 
form of cell death observed (8; 11). It is a highly orchestrated programmed cell death 
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characterized by cell cytoskeleton network rupture, leading to cytoplasmic membrane 
breakage, cell shrinkage, and DNA fragmentation (8; 11). Cardiac myocyte apoptosis is 
mediated by two distinct pathways; extrinsic and intrinsic (9). Extrinsic pathway is 
triggered by extracellular death ligands such as FAS, tumor necrosis factor (TNF)-α, 
and TRAIL, while intrinsic pathway is mediated through multiple Caspases (9).  
Cardiac myocyte apoptosis in the infarct and peri-infarct area activates cardiac 
fibroblasts, which are the main cellular modulators of cardiac fibrosis. They control extra 
cellular matrix (ECM) turn over through secretion of matrix metalloproteinases (MMPs), 
otherwise called Matrixins, and their direct inhibitors; tissue inhibitor of 
metalloproteinases (TIMPs) (19; 22; 33; 38). Imbalance between TIMPs and MMPs 
expression has been documented in MI and is known to precipitate collagen deposition 
in the interstitial and vascular spaces, leading to stiffening of the left ventricle, fibrosis 
and cardiac dysfunction (7; 12; 21). Optimal contractile function relies on the integrity of 
the syncytial myocardium which contracts rhythmically during each cardiac cycle to 
pump the blood out of the cardiac chambers. It is then inevitable that death of cardiac 
cells and accumulation of stiff collagen deposits within the infarct area would 
dramatically impact contractile function, eventually leading to heart failure (6; 32).  
Cell Transplantation in the Infarcted Myocardium 
Cell transplantation therapies to replace dead heart cells and to prevent adverse 
cardiac remodeling following MI have been extensively investigated. Such cells include 
skeletal myoblasts, neo-natal and adult cardiac myocytes, human umbilical cord blood 
cells (UCBCs), endothelial progenitor cells (EPCs), embryonic stem cells (ESCs, bone 
marrow stem cells (BMSCs), mesenchymal stem cells (MSCs), induced pluripotent stem 
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cells (iPSCs) and cardiac stem cells (CSCs) (1; 5). Unequivocally, transplanted cells 
showed some regenerative capabilities, however, cell survival rate and differentiation 
were limited post-transplantation (1; 5; 27; 28). Furthermore, ESCs transplantation 
involves immune response, teratoma formation and ethical concerns. iPSCs and 
BMSCs on the other hand have limited engraftment and may induce tumorigenesis (1). 
Additionally, MSCs were shown to induce bone formation which greatly interferes with 
the myocardium contractility (1). In light of all these limitations, it is imperative to identify 
ways to improve existent cell therapies or identify a new cell population for cardiac 
regeneration. 
One very promising characteristic of transplanted cells is their ability to influence 
injured myocardium through paracrine mechanisms. Indeed, many factors released 
from these cells have been demonstrated to boost cardiac cell self-renewal [(Insulin 
Growth Factor (IGF), Hepatic Growth Factor (HGF) and Stem Cell Factor (SCF)], 
neovascularization [Vascular Endothelial Growth Factor (VEGF) and Fibroblast Growth 
Factor-9 (FGF-9)], and inhibition of adverse cardiac remodeling [Tissue Inhibitor of 
Metalloproteinases-1 (TIMP-1)] (17; 21; 36; 37). Therefore, direct delivery of factors 
released by stem cells to repair the damaged myocardium opens a new avenue for 
cardiac regeneration. 
Endogenous Cardiac Stem Cells 
The identification of cardiac stem cells (CSCs) greatly challenged the belief that 
the heart is a post mitotic organ, therefore increasing enthusiasm among scientific 
community in their quest to repair the damaged heart. CSCs have been localized 
throughout the myocardium in clusters called niches (29). They were isolated from the 
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postnatal and adult human hearts and other mammalian species (1; 23; 29; 34). They 
exhibit capacity to self-renew and differentiate into cardiomyocytes, smooth muscle 
cells, and endothelial cells in appropriate conditions (1; 23; 29; 34). Different sub-
populations of CSCs have been identified based on extra cellular markers, such as side 
population (SP) cells, cardiac progenitor cells (CPCs), Sca-1+ve cells, cardiosphere cells, 
Isl1+ve cells, and c-kit+ve cells, which are still the most abundant and most extensively 
characterized CSCs (1; 5; 29). CSCs are believed to participate in cardiac cell turn over 
and homeostasis in the healthy and injured organ. However, the reported rate of 
myocyte regeneration following MI is rather low; suggesting a limited regenerative 
potential of these resident stem cells (1; 5; 18; 27; 28). Therefore, identifying 
mechanisms to boost endogenous CSCs activation and participation in cardiac repair 
following MI appears as the most promising strategy for MI patients. 
TIMP-1 in Cardiac Remodeling 
Following MI, a maladaptive cardiac remodeling takes place leading to 
decreased cardiac performance. The gross pathological changes involved in cardiac 
remodeling include massive cardiac myocyte cell loss through apoptosis, increased 
infiltration of collagen fibers throughout the infarct zone (fibrosis)  and cardiac myocyte 
hypertrophy leading to deregulated contractile function (2; 3). Cardiac fibroblasts, the 
main cellular modulators of cardiac fibrosis, lead to overstimulation of MMPs and 
downregulation of their direct inhibitors TIMPs (19; 22; 33; 38).  MMPs are a family of 
endopeptidases which play a role in aberrant production of ECM proteins leading to 
adverse ventricular architecture post-MI (31; 38).  Tissue inhibitors of 
metalloproteinases 1 to 4 (TIMPs 1-4) are endogenous protease inhibitors of MMPs (31; 
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38).  TIMPs non-covalently bind the active site of pro-MMP, preventing its activation (31; 
38).  In the heart, decreased expression of TIMP-1 was reported following MI, 
correlating with enhanced expression of both MMP-2 and 9 (14; 22; 38). Additionally, up 
regulation of TIMP-1 in the MI heart by direct delivery of TIMP-1 protein or vector to the 
peri-infarct area has demonstrated decreased overall infarct size and infiltrated fibrosis 
(20). TIMP-1 has additionally been shown to be anti-apoptotic in cardiac and non-
cardiac cell lines (12; 21; 25; 26). Based on these reported beneficial effects, we 
generated embryonic stem (ES) cells overexpressing TIMP-1 factor (ES-TIMP-1 cells). 
When transplanted to the MI heart, these cells demonstrated limited engraftment to the 
host myocardium; however, collected data showed a significant decrease in adverse 
cardiac remodeling parameters as well as improved functional capacity of the heart 
(19). Whether the reported beneficial effects are the result of TIMP-1 released by 
transplanted cells alone or other factors also released by these cells remains obscure. 
TIMP-1 in Cardiac Differentiation 
According to previous studies, ~ 10 % of transplanted stem cells survive in the 
host milieu following transplantation (5; 23; 34). Consequently, limited cardiac myocyte 
differentiation is reported from these cells (1; 20; 34). Therefore, efficacy of cell 
transplantation therapy for myocardial regeneration remains a major challenge. Multiple 
attempts were made to improve aforementioned statistics using various growth factors, 
such as vascular endothelial growth factor (VEGF), transforming growth factor -2 
(TGF2) , insulin-like growth factor-1 (IGF-1) and (IGF-2), fibroblast growth factor-2 
(FGF-2), FGF-4 and epidermal growth factor (EGF) (35-37). Additional factors 
examined include bone morphogenetic protein-2 (BMP-2), Interleukin-6 (IL-6) and 
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Activin-A. Results from these studies described relative improvement in survival plus 
differentiation rate of transplanted cells, which remains insufficient to restore pre-MI 
normalcy (1).  
Involvement of TIMP-1 in cell proliferation has been demonstrated in various cell 
types; however, whether TIMP-1 can promote stem cell differentiation is still unknown.  
In our previously published work, we were able to enhance ES cell engraftment, 
survival, and differentiation post transplantation in the MI heart by engineering them to 
over-express TIMP-1 (20). Indeed, transplanted ES-TIMP-1 cells showed significantly 
increased cardiac myocyte differentiation compared to non-engineered ES cells 
demonstrating the role of TIMP-1 in stem cell differentiation. Based on this data, we 
postulated that TIMP-1 released by ES-TIMP-1 cells may additionally activate 
endogenous cardiac stem cells (CSCs) that express both CSC marker (c-kit) and TIMP-
1 receptor (CD63), leading to cardiac cell differentiation and myocardial regeneration 
post MI injury.  
CD63 marker is a cell surface receptor for TIMP-1 and a member of the 
tetraspanin family (13; 15; 24). It is expressed in multiple cell types including cardiac 
myocytes, endothelial cells and MSCs. However, no one has previously reported 
existence of a CSC population which expresses CD63 marker.  Furthermore, CD63 
activation by TIMP-1 was shown to activate non-canonical β-catenin pathway leading to 
enhanced cell proliferation in various cell types (25). However, whether activation of 
CD63/β-catenin pathway in CD63+ve/c-kit+ve CSCs can trigger cardiac differentiation is 
completely unknown. 
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Rationale and Aims 
MI is a leading cause of death in the western world (54). The reported mortality 
rate following MI is caused by the dramatic myocardium loss consecutive to ischemia 
(5; 6; 30). Additionally, the pool of CSCs discovered in the heart are unable to 
repopulate the infarcted myocardium with functional cardiac myocytes and vascular 
cells to compensate for the millions of cells lost during an MI event (1; 5). To date, major 
efforts have been made to salvage as much myocardium as possible in the first hours 
following MI; however, the permanent damage caused by cell death eventually leads to 
recurrent MIs and heart failure. Recently, regenerative medicine via cell transplantation 
therapy has excited the scientific community as it offers the potential to repopulate the 
infarcted area with functional cardiac myocytes (2). Somatic, iPS, adult and embryonic 
stem cells have been utilized to replenish the myocardium with mitigated results (1). Our 
engineered ES-TIMP-1 cells on the other hand demonstrated improved engraftment and 
differentiation following transplantation when compared to regular ES cells (20). Based 
on this data we postulated that TIMP-1 might be utilized to boost dormant endogenous 
cardiac stem cells (CSCs) that express TIMP-1 receptor (CD63) leading to cardiac cell 
differentiation and myocardial regeneration post MI injury. 
  The goal of the first study was to demonstrate existence of a CSC population 
positive for c-kit (CSC marker) as well as CD63 (TIMP-1 receptor) from isolated murine 
CSCs. We hypothesized that TIMP-1 released by ES-TIMP-1 cells activates isolated 
CD63+ve/c-kit+ve CSCs, enhancing their proliferation, cardiac gene expression, and 
differentiation into major cardiac cell types.  To test our hypothesis, the following aims 
were proposed: 
1. Determine the existence of CD63+ve/c-kit+ve CSCs in isolated murine CSCs. 
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2. Assess the impact of ES-TIMP-1-CM and TIMP-1 on CD63+ve/c-kit+ve CSCs 
proliferation and differentiation in vitro. 
3. Identify the mechanism that mediates CD63+ve/c-kit+ve CSCs proliferation and 
differentiation in vitro. 
Within the second study, we aimed at identifying CD63+ve/c-kit+ve CSCs in vivo as 
well as verifying the ability of TIMP-1 to activate these cells following MI. The goal of 
this study was to validate whether intramyocardial delivery of ES-TIMP-1-CM or TIMP-1 
would activate CD63+ve/c-kit+ve CSCs, enhance their proliferation and differentiation into 
major cardiac cell types and replenish the lost myocardium. We hypothesized that 
TIMP-1 transplantation into the infarcted myocardium targets CD63+ve/c-kit+ve CSCs, 
binds to its receptor on their surface and activates β-catenin pathway, leading to 
enhanced cell proliferation and differentiation.  To test our hypothesis, we proposed the 
following aims: 
1. Determine the existence of CD63+ve/c-kit+ve CSCs in C57BL/6 and TIMP-1 KO 
peri-infarcted hearts and verify the effect of intramyocardial delivery of TIMP-1 on 
their proliferation.  
2. Verify the effect of intramyocardial delivery of TIMP-1 on CD63+ve/c-kit+ve CSCs 
differentiation following MI.  
3. Identify mechanisms by which TIMP-1 mediates CD63+ve/c-kit+ve CSCs 
proliferation and differentiation in vivo.  
Finally, within the third study, we evaluated the impact of TIMP-1 transplantation 
on adverse cardiac remodeling in the infarcted myocardium of C57BL/6 and TIMP-1 KO 
mice.  The goal of this study was to demonstrate that TIMP-1 is a multifunctional protein 
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that not only enhances cardiac proliferation and differentiation but also prevents cardiac 
cell death and fibrosis leading to overall better cardiac function.  We hypothesized that 
TIMP-1 would significantly inhibit cardiac apoptosis, fibrosis and improve cardiac 
function 14 days post cardiac transplantation compared to ESCM treatment leading to 
improved contractile function.  To test our hypothesis, we proposed to address the 
following aims: 
1. Evaluate the anti-apoptotic effect of TIMP-1 transplanted into the host 
myocardium following MI. 
2. Evaluate the anti-fibrotic effect of TIMP-1transplanted into the host myocardium 
following MI. 
3. Determine the impact of transplanted TIMP-1 infarct size and cardiac function 
two weeks post-MI. 
The long term goal of our research is to identify a multi-functional protein for 
cardiac repair and regeneration following MI which targets endogenous CSCs, inducing 
their proliferation and differentiation into all cardiac cell types, while effectively inhibiting 
apoptosis and fibrosis.  Identification of such factor as well as its targeted CSC 
population would provide a strong foundation for cardiac regeneration research.   
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CHAPTER TWO: A CD63+ve/C-KIT+ve STEM CELL POPULATION ISOLATED FROM 
THE MOUSE HEART 
Abstract 
Cardiac cell regeneration from endogenous cardiac stem cells (CSCs) following 
MI is rather low. Therefore, identifying mechanisms to boost endogenous CSC 
activation and participation in cardiac repair appears to be the most promising strategy 
for MI patients. We previously engineered tissue inhibitor of metalloproteinases-1 
(TIMP-1) overexpressing embryonic stem (ES-TIMP-1) cells and transplanted them into 
the infarcted murine heart. Collected data demonstrated that TIMP-1 enhanced 
transplanted ES cell engraftment, survival and differentiation into cardiac myocytes post 
transplantation. Therefore, we postulated that there may be a new stem cell population 
present in the heart that is regulated by extracellular protein TIMP-1. Furthermore, we 
hypothesized that this cell population has a potential for cell proliferation and 
differentiation into cardiac cell types. Therefore, we isolated CSCs from four weeks old 
C57BL/6 mice and cultured them in vitro in presence of ESCM, ES-TIMP-1-CM or 
TIMP-1. Our immunostaining data demonstrated the existence of a novel CSC sub-
population, CD63+ve/c-kit+ve. When treated with TIMP-1, these cells showed significantly 
(p<0.05) increased proliferation rates compared to control cells, enhanced TIMP-1 
receptor (CD63), along with improved expression of phospho and total β-catenin 
proteins as demonstrated by western blot analysis. Next, we demonstrate significantly 
(p<0.05) improved cardiac myocyte, vascular smooth muscle cell, and endothelial cell 
differentiation. Furthermore, our RT-PCR data shows increase in cardiac gene (GATA-
4, Mef2C, and Nkx-2.5) expression when compared to ESCM and control cells. 
Collectively, this data, for the first time, establish the existence of a new CD63+ve/c-kit+ve 
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CSC sub-population that has a significant potential for proliferation and differentiation 
into cardiac cell types once stimulated with TIMP-1. 
Keywords:  Cardiac Stem Cells, TIMP-1, c-kit, CD63, β-catenin, proliferation, 
differentiation. 
Introduction 
The identification of cardiac stem cells (CSCs) in the adult heart greatly 
challenged the belief that the heart is a terminally differentiated organ with no 
regenerative capacity [1,2]. This information greatly increased enthusiasm among the 
scientific community in their quest to repair damaged heart tissue following major 
cardiac cell loss consequent to myocardial infarction (MI). CSCs  are localized 
throughout the myocardium in clusters called niches [2]. They exhibit the capacity, both 
in vivo and in vitro, to self-renew and differentiate into three major cardiac cell types 
including cardiac myocytes, vascular smooth muscle (VSM) cells and endothelial cells 
(ECs) [2-4]. Different sub-populations of CSCs have been identified based on 
extracellular markers, such as side population (SP) cells, cardiac progenitor (CP) cells, 
Sca-1+ve cells, cardiosphere cells, Isl1+ve cells and c-kit+ve cells [2]. CSCs are believed to 
participate in cardiac cell turn over and homeostasis in the healthy and injured heart 
[2,3]. However, the reported rate of myocyte regeneration from CSCs following MI is 
rather low suggesting a limited regenerative potential of these resident stem cells [1,2]. 
Therefore, identifying mechanisms to boost endogenous CSC activation and their 
participation in cardiac repair following MI appears to be the most promising strategy for 
MI patients. 
Multiple factors have been shown to promote stem cell recruitment, proliferation 
and differentiation. Such factors include, but are not limited to, insulin growth factor 
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(IGF), hepatic growth factor (HGF), granulocyte-colony stimulating factor (G-CSF), 
vascular endothelial growth factor (VEGF), fibroblast growth factor-9 (FGF-9), and 
transforming growth factor beta-2 (TGF-β2) [5]. Results from these studies described 
relative improvement in cell proliferation and differentiation. However, their efficacy 
remains insufficient to restore the post-MI myocardium to its non-pathological 
architecture and functional capacity [6,7]. Therefore, we hypothesize that there may be 
additional populations of CSCs present in the heart that could be activated by specific 
factors, driving their proliferation and differentiation. 
In our previously published work, we engineered tissue inhibitor of 
metalloproteinases-1 (TIMP-1) overexpressing ES cells and transplanted them into the 
infarcted murine heart [8]. Collected data demonstrated that TIMP-1 enhanced 
transplanted ES cell engraftment, survival and differentiation into cardiac myocytes post 
transplantation [8]. In lieu of our previous findings, we postulated that TIMP-1 released 
by ES-TIMP-1 cells may have additionally activated a subpopulation of endogenous 
CSCs that express the CSC marker (c-kit) and TIMP-1 receptor (CD63).  
To test the hypotheses, we aimed at identifying a subset of CSCs, CD63+ve/c-
kit+ve, from isolated murine CSCs. Next, we verified the effect of ES cell released 
factors, present in their conditioned medium, with or without TIMP-1 (ESCM and ES-
TIMP-1-CM) or TIMP-1 alone on CD63+ve/c-kit+ve CSCs proliferation and differentiation 
rates. Our data will show for the first time that we were able to identify a CD63+ve/c-kit+ve 
sub-population of CSCs that is susceptible to proliferate, express cardiogenic factors, 
and differentiate into major cardiac cell types upon treatment with either ES-TIMP-1-CM 
or TIMP-1 in vitro. 
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Materials and Methods 
Isolation of Cardiac Stem Cells (CSCs) 
CSCs were isolated from 4 to 6 weeks old C57BL/6 mice hearts following 
instructions provided with the Millipore CSCs Isolation kit (Cat# SCR061). In brief, 
hearts were removed from the thoracic cavity, washed, and minced in CSC isolation 
buffer. Next, a cell suspension was created through gentle agitation in dissociation 
buffer for 1 hr and filtered using a self-contained Steriflip® filtration device. The filter 
allows for the separation of larger cellular material while maintaining a sterile 
environment. A differential gradient centrifugation was then applied to the cells, allowing 
for the formation of a clear mid layer containing total CSCs. Isolated CSCs were plated 
on gelatin-coated plates in CSCs maintenance medium (MM) purchased from Millipore 
(Catalog# SMC101). During the first 7 to 12 days, cells gradually adhered to the plate 
and were maintained regularly as per our standard protocol [8].  
Preparation of ESCM, ES-TIMP-1-CM, and TIMP-1 
ES-TIMP-1 cells were generated in our lab as previously described (8). Next, 
condition medium (CM) was prepared by treating ES and ES-TIMP-1 cells with 
Dulbecco’s Modified Eagle Medium (DMEM) containing leukemia inhibitory factor (LIF) 
along with other components as we reported previously (5; 8). LIF was then removed 
and cells were cultured for 48 hrs on gelatin-coated plates. Following incubation, ESCM 
and ES-TIMP-1-CM were collected, filtered, and stored at -20oC. Recombinant mouse 
TIMP-1 was purchased from R&D (cat # 980-MT) as a lyophilizat and reconstituted to a 
concentration of 100µg/ml following manufacturer instructions and stored at -20oC. 
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CSCs treatment with ESCM, ES-TIMP-1-CM, and TIMP-1 
CSCs were cultured in 6 well plates (80,000 cells/well) pre-coated with 0.1% 
gelatin in MM until they adhered to the bottom of the plates.  CSCs were then divided 
into 4 groups (n=4 wells/group); Control (CSCs supplemented with 2ml growth media 
(GM)), ESCM (CSCs supplemented with 2ml of ESCM), ES-TIMP-1-CM (CSCs 
supplemented with 2ml of ES-TIMP-1-CM) and TIMP-1 (CSCs treated with 50ng TIMP-
1 in 2ml GM). Treated cells were incubated for 48 hrs followed by a media exchange 
back to MM in all groups for an additional 24 hrs.  
Plating and Immunostaining Detection of CD63+ve/c-kit+ve CSCs  
 CSCs were cultured in 8 well plates (15,000 cells/well) pre-coated with 0.1% 
gelatin.  Cells were divided, cultured, and treated as aforementioned.  Next, cells were 
washed and fixed with 10% formalin and Triton X for 10 min each followed by 1 hr with 
10% normal goat serum (NGS; Vector Laboratories). To determine whether cells 
express CD63 and c-kit markers, cells were incubated with anti-c-kit (1:50; Santa Cruz) 
or anti-MLA-CD63 (1:500; Bios) rabbit monoclonal antibodies diluted in 10% NGS for 1 
hr at room temperature or overnight at 4oC. Cell were then washed and incubated for 1 
hr with secondary antibodies (goat anti-rabbit Alexa Fluor 568 (c-kit) or 660 (CD63)) at a 
concentration of 1:20 diluted in 1x PBS. Total nuclei were detected by mounting each 
section with Antifade Vectashield medium containing 4’,6-diamino-2-phenylindole 
(DAPI; Vector Laboratories). Olympus and confocal fluorescence microscopes were 
used to visualize and quantify CD63+ve/c-kit+ve cells over total nuclei. Data are presented 
as % of c-kit+ve cells over DAPI and % CD63+ve/c-kit+ve cells/total c-kit+ve cells. 
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Immunostaining Determination of CD63+ve/c-kit+ve CSCs Differentiation into 
Cardiac Myocytes, VSM Cells, and ECs 
To verify whether treatment with ES-TIMP-1-CM or TIMP-1 can trigger CSC 
differentiation into cardiac myocytes, VSMs, and/or ECs in vitro, CD63+ve/c-kit+ve cells 
were stained with either sarcomeric (Src) α-actin, smooth muscle (SM) α-actin or CD31, 
respectively [9].  After 1 hr incubation in NGS, cells were incubated with rabbit anti-
CD31 monoclonal antibody (1:25, Santa Cruz Biotechnologies) prepared in 10% NGS, 
followed by FITC-conjugated goat anti-rabbit IgG secondary antibody (1:50, Invitrogen) 
for 60 min. A mouse anti-mouse kit (MOM, Vector Laboratories) was used for SM and 
Src-α-actin staining. After blocking, cells were incubated with anti-SM and anti-Src α-
actin antibodies (1:50 and 1:100 respectively, Sigma) for 30 min followed by an IgG 
antibody and fluorescein avidin solution for 5 and 10 min each. Stained cells were then 
mounted with Vectashield antifade medium containing DAPI (Vector Laboratories) for 
nuclear visualization. Olympus, confocal microscope and Image J software were used 
to quantify cardiac cell differentiation of CD63+ve/c-kit+ve cells using the following 
formulas: % cardiac myocyte differentiation = Cells positive for Src α-actin, c-kit, and 
CD63 over DAPI x 100. % VSM differentiation = Cells positive for SM α-actin, c-kit, and 
CD63 cells over DAPI x 100. % ECs differentiation = Cells positive for CD31, c-kit, and 
CD63 cells over DAPI x 100. 
Cell Proliferation Assay 
 Previously treated cells were trypsinized and re-seeded on a 96 well plate at a 
density of 104 cells/well supplemented with MM for 48 hrs. Next, cell proliferation was 
measured using a tetrazolium salt cell proliferation assay kit (Cat# 10008883; Chayman 
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Chemical). In brief, each well received 10µl of reconstituted tetrazolium salt solution and 
the plate was incubated at 37oC on an orbital shaker for 3 hrs. Finally, absorbance of 
each sample was read using a microplate reader at a 450nm. Measured absorbance 
directly correlated with proliferation rate and was plotted as a bar graph. 
Western Blot Detection of CD63, phospho (p) and total β-catenin Proteins 
Expression 
To determine CD63, phospho (p) and total β-catenin expression on isolated 
CSCs as well as the effect of TIMP-1 on their expression, western blot analysis was 
performed on cell lysates obtained from all four treatments groups as previously 
described [10]. In brief, an equal amount of protein (100ug) was loaded on a 10% 
polyacrylamide gel and subjected to electrophoresis at 150V for 1 hr. The gel was then 
transferred for 45 min to a polyvinylidene fluoride membrane (BioRad) using a semi-dry 
Immuno-Blot (Bio-Rad) at 15V. The membranes were blocked with 5% skim milk for 1 
hr, incubated with primary rabbit antibodies (CD63/MLA1; cat # ABIN687742), (β-
catenin (6B3) ; cat # 9582), phospho-β-catenin (Ser33/37/Thr41; cat # 9561, Cell 
signaling), and β-actin (cat # 4967L from Cell Signaling) for one hr on an orbital shaker 
at room temperature or at 4oC overnight, and incubated with anti-rabbit IgG horseradish 
peroxidase secondary antibody (Cat # 7074S; Cell Signaling) for an additional 1 hr. 
Blots were detected with Pierce® ECL Western Blotting Substrate (Thermo Scientific). 
Real-Time PCR for GATA-4, Mef2C and Nkx-2.5  
Cells were plated as previously described and total RNA was extracted using the 
TRI® reagent protocol (Cat # T9424; Sigma Aldrich) (11). In brief, cells were lysed using 
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1ml TRI reagent in an RNase free environment followed by a separation step in 
chloroform and RNA precipitation in isopropyl alcohol. cDNA was synthesized from 1μg 
total RNA using Superscript II reverse transcriptase and random primers (Bio-Rad). 
Next, real-time quantitative PCR was performed using a CFX96™ Real-Time System 
(Bio Rad). Supermix 2X (Life Technologies) containing FAM fluorescent dye and dNTPs 
was added to the reaction mixture containing cDNA template and forward and reverse 
primers.  GATA-4, Mef2C, Nkx-2.5 and GAPDH primer assays were purchased from 
Life Technologies. The following cycling conditions were used: 95˚C for 5 min followed 
by 35 cycles of amplification (denature at 95˚C for 15 seconds and combined annealing 
/extension at 60˚C for 60 seconds). The relative fold expression of GATA-4, Mef2C, and 
Nkx-2.5 in each group was normalized against GAPDH and plotted. 
Statistical Analysis 
Data was analyzed using One-way analysis of variance (ANOVA) followed by the 
Tukey Test.  Data is presented as a mean ± SEM and statistical significance assigned 
when p-value <0.05. 
Results 
Identification of CD63+ve/c-kit+ve Population from Isolated Murine CSCs. 
CSCs were isolated from adult C57BL/6 mice hearts and cultured in vitro in the 
presence of ESCM, ES-TIMP-1-CM or TIMP-1. Immunostaining to identify c-kit+ve and 
CD63+ve/c-kit+ve CSCs was performed. Our data demonstrate that about 80% of isolated 
CSCs were c-kit+ve (Figure1B) prior to treatment and up to 60% of these cells shared the 
CD63 marker (Figure 1A and C). Following treatment, our data demonstrate the % of c-
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kit+ve cells significantly increased in the ES-TIMP-1-CM group compared to the control 
group (p<0.05, ES-TIMP-1-CM: 94%±1.91% vs. control: 76.5%±0.5%, Figure 1B). 
However, the percent of double positive CD63+ve/c-kit+ve CSCs significantly increased 
with both ES-TIMP-1-CM (95.5%±1.19%) and TIMP-1 (88.11%±4.3%) treatments 
compared to ESCM (66.8%±1.06%) and control (60.61%±5.8%) cells (p<0.05, Figure 
1C). Moreover, CD63, (p) and total β-catenin expression significantly increased upon 
CSC treatment with TIMP-1 compared to control cells (p<0.05, Figures 1D-F). This data, 
for the first time, identify a subset of CSCs that are CD63+ve/c-kit+ve and TIMP-1 
enhances CD63 expression on their surface and β-catenin downstream of CD63 (Figure 
1).   
TIMP-1 Enhances CD63+ve/c-kit+ve CSC Proliferation in vitro 
The effect of TIMP-1 on CD63+ve/c-kit+ve CSC proliferation was examined (Figure 
2). Our data show enhanced cell proliferation in all treatment groups compared to 
control cells (p<0.05, Figure 2A and B). Of note, although no significant difference 
among treatment groups (ES-CM, ES-TIMP-1-CM, and TIMP-1) was achieved, it is 
worth noting that TIMP-1 alone was able to induce a similar proliferation rate as that in 
the ES-TIMP-1-CM group (Figure 2B). This data demonstrate that TIMP-1 alone can 
promote CSC proliferation in vitro. 
TIMP-1 Enhances Isolated CD63+ve/c-kit+ve CSC Differentiation into Cardiac 
Myocytes, VSM Cells, and ECs 
Triple immunostaining targeting newly differentiated CD63+ve/c-kit+ve CSCs 
expressing either Src α-actin (cardiac myocytes), SM α-actin (VSM cells) or CD31 (ECs) 
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was performed (Figure 3). Panels A, C, and E demonstrate confocal representative 
images of CD63+ve/c-kit+ve CSCs undergoing cardiac myocyte, VSM cell, or EC 
differentiation, respectively, with c-kit+ve cells shown in red (a,f and k), CD63+ve cells 
shown in purple (b,g, and l), total nuclei shown in blue (c,h, and m), Src α-actin+ve, SM 
α-actin+ve, or CD31+ve cells shown in green (d,i, and n, respectively), and merged 
images of all four colors in e,j, and o. Our quantitative data revealed control and ESCM 
groups underwent a similar rate of cardiac myocyte differentiation, while ES-TIMP-1-CM 
and TIMP-1 treatments significantly enhanced this parameter relative to the control and 
ESCM groups (p<0.05, ES-TIMP-1-CM; 31.24%±1.5% and TIMP-1; 29.39%±1.5% vs. 
Control; 17.09%±0.6% and ESCM; 18.49%±0.9%, Figure 3B). A similar differentiation 
pattern was also noted for VSM cells (p<0.05, ES-TIMP-1-CM; 27.94%±0.8% and 
TIMP-1; 24.31%±1.6%) compared to control and ESCM groups (Control; 13.9%±0.35% 
and ESCM; 14.93%±1.11%, Figure 3D) and ECs (p<0.05, ES-TIMP-1-CM; 
14.7%±0.25% and TIMP-1; 15.9%±0.5%, Figure 3F) compared to control and ESCM 
groups (Control; 9.01%±0.43% and ESCM; 10.53%±0.32%, Figure 3F). This overall 
data demonstrate, for the first time, that TIMP-1 can trigger isolated CD63+ve/c-kit+ve 
CSC differentiation into the three major cardiac cell types (cardiac myocytes, VSM cells, 
and ECs). 
TIMP-1 Enhances Expression of Cardiac Genes in Isolated CD63+ve/c-kit+ve CSCs  
To verify expression of pro-cardiac markers GATA-4, Mef2C, and Nkx-2.5 
following TIMP-1 treatment, RT-PCR analysis was performed (Figure 4). Our data 
demonstrate no significant change in GATA-4 (Figure 4A), Mef2C (Figure 4B), and Nkx-
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2.5 (Figure 4C) mRNA levels in ESCM treated cells compared to control. However, cells 
treated with ES-TIMP-1-CM and TIMP-1 showed significantly increased expression of 
the three genes; GATA-4 (p<0.05, ES-TIMP-1CM; 6.81±1.02 and TIMP-1; 7.39±1.01 vs 
Control; 1±0.71 and ESCM; 1.35±0.23, Figure 4A), Mef2C (p<0.05, ES-TIMP-1CM; 
6.37±0.99 and TIMP-1; 7.34±0.33 vs Control; 1±0.8 and ESCM; 0.58±1.18, Figure 4B), 
and Nkx-2.5 (p<0.05, ES-TIMP-1CM; 1.55±0.21 and TIMP-1; 1.4±0.03 vs Control; 1±0.1 
and ESCM; 0.86±0.06, Figure 4C).  This data further confirm that TIMP-1 enhances 
CD63+ve/c-kit+ve CSC differentiation as demonstrated by increased cardiac gene 
expression. 
Discussion 
Several CSC sub-populations have been described in the adult heart. However, 
the role of each category in myocardial regeneration remains an open question [2,3]. 
Notably, endogenous cardiac progenitor cells were shown to give rise to differentiated 
progeny including cardiac myocytes, VSM cells and ECs, in vitro as well as in vivo. 
Nonetheless, the extent of cardiac regeneration observed in the post-MI heart by CSCs 
remains insufficient to regain pre-infarct homeostasis [2,3,12]. Therefore, investigating 
alternative ways to enhance the differentiation potential of endogenous CSCs remains 
an important area of cardiac research. In the present study, we identify a novel sub-
population of CSCs, CD63+ve/c-kit+ve. When treated with TIMP-1, they showed 1) 
increased proliferation rates compared to control cells, 2) enhanced CD63, (P) and 
Total β-catenin expression, 3) significantly improved cardiac myocyte, VSM cell and EC 
differentiation, and 4), increased cardiac gene (GATA-4, Mef2C and Nkx-2.5) 
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expression. Taken together, this data, for the first time, establish the existence of a CSC 
sub-population, which is CD63+ve/c-kit+ve and is specifically targeted by TIMP-1. 
Furthermore, in the presence of TIMP-1, these cells undergo proliferation and 
differentiation into major cardiac cells in vitro. We also postulate that TIMP-1 induced 
CSC proliferation and differentiation is mediated through activation of CD63/β-catenin 
pathway; however, additional experiments are required to confirm this hypothesis. 
TIMP-1 is a glycoprotein that is ubiquitously expressed in numerous human cells 
and tissues [8]. It is expressed in the normal heart to repress matrix metalloproteinases 
(MMPs), which are responsible for extracellular matrix breakdown [8]. In the post-MI 
heart, TIMP-1 has been extensively studied for its protective role against aberrant 
collagen accumulation and fibrosis [8]. Furthermore, its involvement in cell proliferation 
has been demonstrated in various cell types including human erythroid progenitor cells 
and cancer cells [13,14]. However, whether TIMP-1 can promote stem cell 
differentiation is still unknown.  In our previously published work, we were able to 
enhance ES cell differentiation post-transplantation in the post-MI heart by engineering 
them to over-express TIMP-1[8]. Therefore, we speculated that beyond its MMP-
dependent activity, TIMP-1 released by ES-TIMP-1 cells may additionally act as a 
differentiation and proliferation factor on endogenous CSCs.        
To test this hypothesis, we isolated murine CSCs and performed immunostaining 
analysis to identify CD63+ve/c-kit+ve cells. Our data revealed the presence of a 
CD63+ve/c-kit+ve sub-population, which makes up almost 60% of the whole c-kit+ve cell 
population. Moreover, treatment with ES-TIMP-1-CM and TIMP-1 induced an increase 
in CD63 expression on these cells as well as enhanced their proliferation rate to about 
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80% of total c-kit+ve CSCs. CD63 is a transmembrane protein belonging to the 
tetraspanin family and has been shown to be expressed in multiple cell types including 
cardiac myocytes, ECs and human mesenchymal stem cells (hMSCs) [14,15]. However, 
we are first to report its expression by CD63+ve/c-kit+ve CSCs. This data strongly support 
our hypothesis and is in accordance with previously published work demonstrating 
enhanced hMSCs proliferation through TIMP-1/CD63 interaction on the cell surface 
[14]. 
Next, we aimed at investigating whether TIMP-1 alone could influence CD63+ve/c-
kit+ve CSC differentiation in vitro. Previously published studies demonstrated that ESCM 
contains factors such as IGF1/2, bone morphogenetic protein-2 (BMP-2), platelet-
derived growth factor (PDGF) and VEGF that can promote cardiac differentiation [5]. 
However, none of these factors were able to promote significant cardiac differentiation 
capable of restoring pre-MI capacity [16]. The role of TIMP-1 in cell differentiation, on 
the other hand, has been the center of debate.  In fact, TIMP-1 was reported to promote 
oligodendrocyte differentiation and enhance central nervous system (CNS) myelination 
as well as induce differentiation of germinal center B cells [17], while others claim it 
inhibits hMSCs differentiation and promotes cell proliferation through modulation of 
Wnt/β-catenin pathway [14]. Its implication in cardiac differentiation, however, has not 
yet been delineated. In the present study, we provide evidence that TIMP-1 promotes 
CD63+ve/c-kit+ve CSCs differentiation into the three major cardiac cells. 
To further establish the involvement of TIMP-1 in CD63+ve/c-kit+ve CSC 
differentiation, we measured cardiac gene expression on isolated CSCs. GATA-4, 
Mef2C and Nkx-2.5 are cardiogenic factors first expressed during embryonic 
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development to promote cardiac differentiation [18-21]. In the adult organ, these factors 
are mainly expressed by adult stem cells undergoing cardiac differentiation. More 
particularly, GATA-4 and Nkx-2.5 are linked to myocyte differentiation while Mef2C is 
linked to both cardiac myocyte and vascular cell differentiation [20-21]. Based on these 
previous findings, increased expression of these genes was assumed to be an indicator 
of CSC differentiation. Interestingly, our data show ES-TIMP-1-CM and TIMP-1 
significantly enhanced expression of all three cardiac genes while ESCM treatment did 
not.   
Taken together, our study demonstrates the existence of a CD63+ve/c-kit+ve CSC 
population that is susceptible to proliferation and differentiation into cardiac myocytes 
and vascular cells in vitro upon treatment with TIMP-1. Furthermore, we show that 
cardiac differentiation is mediated through TIMP-1 binding to its receptor, CD63, leading 
to activation of β-catenin protein that enhances cardiac gene expression (GATA-4, 
Mef2C and Nkx-2.5). However, it is still unclear how β-catenin mediates cardiac 
myocyte or vascular cell differentiation when receiving one unique signal, TIMP-1. 
Furthermore, the ability of TIMP-1 to enhance CD63+ve/c-kit+ve CSC differentiation in vivo 
has yet to be attempted. Therefore, future studies aiming at identifying CD63+ve/c-kit+ve 
CSCs in vivo, their localization in respect to the infarct zone following MI, as well as 
investigating their ability to migrate, proliferate and differentiate upon TIMP-1 
transplantation is warranted.  
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Figures  
  
 
Figure 1. Identification of CD63+ve/c-kit+ve CSC Population from Isolated CSCs. 
 Panel A depicts representative confocal images of immunostained CD63+ve/c-
kit+ve CSCs with c-kit+ve cells shown in green (a), CD63+ve cells shown in red (b), DAPI 
shown in blue (c) and merged images of all three channels (d). Boxed area with arrow 
pointing towards it within d depicts an enlarged cell. Scale bar= 300µm. Graph 1B 
demonstrates percent c-kit+ve CSCs/DAPI results. Figure 1C represents quantification 
analysis of percent CD63+ve/c-kit+ve CSCs/ c-kit+ve cells. Figures 1D-F depict 
densitometry analysis of CD63, β-catenin and (P)-β-catenin respectively over β-actin via 
western blot. Data was collected from n=4-5 experiments per group.*p<0.05 vs. Control 
and #p<0.05 vs. ESCM.  
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Figure 2. TIMP-1 Enhances CD63+ve/c-kit+ve CSCs Proliferation.  Bright field 
representative images for all four control and treatment groups are depicted in Figure 2, 
panel A (a, c, e, and g). Boxed areas from each photomicrograph are enlarged in A (b, 
d, f, and h). Magnification = 10x. Quantitative data obtained from a proliferation assay 
are depicted in Figure 2B. A.U= Arbitrary units. Data was collected from n=4-5 
experiments per group. *p<0.05 vs. Control and #p<0.05 vs. ESCM.  
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Figure 3. TIMP-1 Enhances CD63+ve/c-kit+ve CSCs Differentiation into Cardiac 
Myocytes, VSMs, and ECs.  Panels A, C, and E demonstrate confocal representative 
images of CD63+ve/c-kit+ve CSCs undergoing cardiac myocyte, VSM cell, and ECs 
differentiation, respectively, with c-kit+ve cells shown in red (a, f and k), CD63+ve cells 
shown in purple (b, g, and l), total nuclei shown in blue (c, h, and m ), Src α-actin+ve, SM 
α-actin+ve, and CD31+ve cells shown in green (d, i, and n), and a merged image of all four 
colors in (e, j, and o). Each merged image contains an enlarged area boxed in the 
corner. Scale bar = 300µm. Figure 3B represents quantitative analysis of percent 
CD63+ve/c-kit+ve /Src-α-actin+ve CSCs over DAPI. Figure 3D represents quantitative 
analysis of percent CD63+ve/c-kit+ve/SM-α-actin+ve CSCs over DAPI. Figure 3F 
represents quantitative analysis of percent CD63+ve/c-kit+ve/CD31+ve cells over DAPI. 
Data were collected from n=4-5 experiments per group. *p<0.05 vs. Control and 
#p<0.05 vs. ESCM.  
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Figure 4. TIMP-1 Enhances Expression of Cardiac Genes in Isolated CD63+ve/c-
kit+ve CSCs.  Figure 4 depicts RT-PCR analysis of pro-cardiac markers GATA-4 (A), 
Mef2C (B), and Nkx-2.5 (C). Data are plotted as mRNA relative fold change vs. control 
group and normalized against GAPDH. Data were collected from n=4 experiments per 
group.*p<0.05 vs. Control and #p<0.05 vs. ESCM.  
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CHAPTER THREE: TIMP-1 ACTIVATED CD63+ve/C-KIT+ve CARDIAC STEM CELLS 
DIFFERENTIATE INTO HEART CELL TYPES AND ENHANCE REGENERATION IN 
THE INFARCTED MYOCARDIUM 
Abstract 
 We previously demonstrated that embryonic stem (ES) cells over-expressing 
tissue inhibitor of metalloproteinase-1 (TIMP-1) have increased potential to engraft and 
differentiate into cardiac myocytes following transplantation in the infarcted heart. 
However, the ability of TIMP-1 to activate endogenous cardiac stem cells (CSCs) and 
enhance their differentiation potential is still unknown. Based on the observed beneficial 
effects of TIMP-1 on transplanted ES cells, we postulated that TIMP-1 released by ES-
TIMP-1 cells may additionally activate endogenous cardiac stem cells (CSCs) that 
express both CSC marker (c-kit) and TIMP-1 receptor (CD63) leading to cardiac 
regeneration in the infarcted myocardium.  Accordingly, C57BL/6 and TIMP-1 KO mice 
underwent coronary artery ligation followed by intramyocardial delivery of 20µl of culture 
media (CC), ES conditioned media (ESCM), ES-TIMP-1-CM or TIMP-1. 
Immunohistochemistry analysis demonstrated a significant (p<0.05) increase in 
CD63+ve/c-kit+ve CSCs following ES-TIMP-1-CM and TIMP-1 treatments compared with 
controls. Interestingly, ratios of CD63+ve/c-kit+ve CSCs were significantly (p<0.05) lower 
in TIMP-1 KO mice compared to C57BL/6 animals. RT-PCR analysis revealed TIMP-1 
KO animals expressed significantly less CD63 and TIMP-1 mRNAs compared to 
C57BL/6 mice. Additionally, activated CD63+ve/c-kit+ve CSCs were able to differentiate 
into cardiomyocytes, endothelial and vascular smooth muscle cells. The differentiation 
rate, however, was more robust in C57BL/6 mice compared to TIMP-1 KO mice. Finally, 
we demonstrated that CSCs differentiation is regulated by CD63/β-catenin pathway. 
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Overall, this study demonstrates that transplantation of TIMP-1 or ES-TIMP-1-CM into 
the infarcted environment activates CD63+ve/c-kit+ve CSC population enhancing their 
proliferation and cardiac regenerative potential through the CD63/β-catenin pathway. 
Keywords:  Myocardial infarction, TIMP-1, Cardiac stem cells, CD63/β-catenin 
pathway. 
Introduction 
The belief that the adult human heart is a post-mitotic organ incapable of  
regenerating itself has long been challenged by multiple studies uncovering the 
existence of small populations of stem cells residing within the myocardium, capable of 
mitotic activity and differentiation into heart cells (1-3). Despite this, the reported rate of 
myocyte regeneration is rather low; suggesting a limited regenerative potential of these 
resident stem cell niches (1; 2; 10; 15; 16). Adult and embryonic stem cell based 
transplantation therapies have gained much interest in the last decade for their ability to 
regenerate injured myocardium (4; 7; 14-16; 18; 19; 23). Despite their varied 
regenerative capabilities, the cell survival rate and differentiation were limited post-
transplantation (1; 2; 15; 16). Nonetheless, the heart still benefits from factors released 
from these cells. These factors were shown to play a role in cell self-renewal [(Insulin 
Growth Factor (IGF), Hepatic Growth Factor (HGF) and Stem Cell Factor (SCF)], 
neovascularization [Vascular Endothelial Growth Factor (VEGF) and Fibroblast Growth 
Factor-9 (FGF-9)], and inhibition of adverse cardiac remodeling [Tissue Inhibitor of 
Metalloproteinases-1 (TIMP-1)] (9; 11; 26-28). 
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Our published data show that tissue inhibitor of metalloproteinases-1 (TIMP-1) 
inhibits apoptosis and fibrosis in the infarcted heart (11). TIMP-1 Knocked out (KO) mice 
showed exacerbated cardiac fibrosis two weeks after MI (12, 21). Furthermore, TIMP-1 
KO mice treated with exogenous delivery of TIMP-1 or PD-166793, a pharmacological 
inhibitor of MMPs, was sufficient to reduce cardiac fibrosis (12). Additionally, we 
previously demonstrated that ES over-expressing TIMP-1 cells have increased potential 
to engraft and differentiate into cardiac myocytes following transplantation in the 
infarcted heart (11). However, the ability of TIMP-1 to activate endogenous CSCs and 
enhance their differentiation potential is still unknown. Based on the observed beneficial 
effects of TIMP-1 on transplanted ES cells, we postulate that TIMP-1 released by ES-
TIMP-1 cells may additionally activate endogenous cardiac stem cells (CSCs) leading to 
cardiac regeneration (11).  
TIMP-1 enhances proliferation of various cell types through regulation of the 
CD63/β-catenin signaling pathway (13). CD63 is a cell surface receptor for TIMP-1 and 
a member of the tetraspanin family. CD63 activation by TIMP-1 induces downstream 
phosphorylation of β-catenin protein. The activated β-catenin then translocates to the 
nucleus, interacts with T-cell factor-1 (TCF-1) transcription factor, and causes 
transcription of target genes Cyclin D1, Survivin and Vascular Endothelial Growth 
Factor (VEGF). If not activated, β-catenin is ubiquitinylated in the cytoplasm and 
degraded through the activity of the Axin complex (5; 6).  
In the previous chapter, we identified a novel cardiac stem cell population, 
CD63+ve/c-kit+ve, from isolated murine CSCs. These cells were able to proliferate and 
differentiate into cardiac myocytes, endothelial (ECs) and vascular smooth muscle 
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(VSM) cells in vitro upon TIMP-1 treatment. However, identification of these cells in the 
MI heart and their ability to promote sufficient cardiac regeneration upon TIMP-1 
treatment is yet to be investigated. 
The involvement of TIMP-1 and CD63/β-catenin pathway in cardiac regeneration 
is not yet understood; therefore, we hypothesized that TIMP-1 enhances cardiac 
regeneration in the MI heart through targeting a unique CD63+ve/c-kit+ve, CSC 
population. These cells upon activation undergo cardiac differentiation resulting in 
overall improved contractile function. Furthermore, we investigated CD63/β-catenin 
pathway as the potential downstream mechanism controlling CSCs differentiation in the 
infarcted heart.  
Materials and Methods 
Preparation of ESCM and ES-TIMP-1-CM 
Embryonic stem (ES) cells overexpressing TIMP-1 factor were generated in our 
lab as previously described (31). ES and ES-TIMP-1 cells were treated with Dulbecco’s 
Modified Eagle Medium (DMEM) containing leukemia inhibitory factor (LIF) along with 
other components as we reported. LIF was then removed and cells were cultured for 48 
hours on gelatin coated plates. Following incubation, cell media enriched (Conditioned 
media, CM) with factors released by both ES (ESCM) and ES-TIMP-1 (ES-TIMP-1-CM) 
cells was collected, filtered, and stored in -20oC (27).  
TIMP-1 Preparation 
Recombinant mouse tissue inhibitor of metalloproteinases (TIMP-1) was 
purchased from R&D (cat # 980-MT) as a lyophilizat and reconstituted to a 
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concentration of 100ug/ml in a mixture of Tris (50mM), CaCl2 (10mM), NaCl (150mM), 
and Brij35 (0.05%) dissolved in sterile double distilled water (ddH2O). Stock solutions 
were aliquoted into 100µl volumes and stored in -20oC. 
Myocardial Infarction and Treatment Administration 
C57BL/6 (cat# 000664) and TIMP-1 KO on C57BL/6 background (B6.129S4-
Timp1tm1Pds/J; Cat# 006243) were purchased from Jackson Laboratories and bred at the 
University of Central Florida (UCF) transgenic animal facility (TAF). All experiments 
were in compliance with the UCF Institutional Animal Care and Use Committee (IACUC) 
guidelines. 8 to 10 weeks old, mice were segregated into five study groups; Sham 
(n=8), MI + Culture Media (CC; n=8), MI+ESCM (n=8), MI+ESTIMP-1-CM (n=8) and 
MI+TIMP-1 (n=8). Myocardial infarction (MI) surgery was performed as previously 
reported (9; 27; 29; 30). In brief, animals were sedated with 4% isoflurane and 2% 
oxygen through an endotracheal intubation system (Minivent Type 845; Harvard 
Apparatus). Animals were injected with an intramuscular dose of Buprenorphine 
(0.5mg/kg) prior to surgery and 2-3 hours post-surgery to aid in pain relief. During the 
procedure, the chest was shaved and a left thoracotomy was performed. The heart was 
exposed and visualized under a light microscope to locate the Left Anterior Descending 
(LAD) coronary artery coming down the left atrium and branching onto the left ventricle.  
Using a surgical suture needle (Monofilament polypropylene non-absorbable suture, 
7/0; cat # 8703P; CP Medical, Portland), a node was made around the LAD and the 
artery was ligated. Artery ligation was confirmed by visualizing a bleaching area around 
the ligation site, demonstrating a lack of blood supply to the ventricle. 20µl of CC, 
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ESCM, ES-TIMP1-CM or TIMP-1 (200µg/kg of body weight) were injected at two sites 
within the periphery of the bleached area (peri-infarct area) using a 700 Series 
MICROTITER Syringe supplemented with a gauge floating needle (Hamilton CO., 
Nevada). Sham operated animals underwent complete surgery; however, the node 
created around the LAD was left loose. The chest was closed and animals were allowed 
to recover. Two weeks post-surgery, animals were sacrificed via isoflurane over-
exposure and cervical dislocation.  
Preparation of Paraffin Sections 
Mice hearts were harvested upon sacrifice and subjected to histological 
evaluation as previously detailed (9; 27; 29; 30). The bottom portion containing both 
ventricles was fixed in paraformaldehyde (PFA 4%) for 24 to 48 hours, dehydrated in 
increasing concentrations of ethanol and embedded in paraffin. Resulting blocks were 
subsequently sectioned using our microtome and 5um thickness sections were 
generated and placed on microscope slides (Fisher Scientific). Prior to any staining, 
sections were incubated for 30 minutes at 60oC to allow extra paraffin to melt. Complete 
deparaffinization and rehydration was achieved by subsequent dipping in xylene two 
times for 5 minutes,  xylene: absolute alcohol (50:50), absolute alcohol (100%), and 90, 
70, 50 and 30% ethyl alcohol solutions for 5 minutes each. Tissues were finally washed 
in distilled water and phosphate-buffered saline (PBS 1X) for an additional 5 minutes.  
Immunostaining Identification of CD63+ve/c-kit+ve CSCs in the Heart  
To determine the existence of a subset CSC population expressing CD63 marker 
in the murine heart, a double immunostaining for c-kit (CSCs marker) and CD63 (TIMP-
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1 receptor) was performed on tissue sections from 7 to 8 animals per group from both 
C57BL/6 and TIMP-1 KO mice. In brief, sections were incubated with 10% normal goat 
serum (NGS; Vector Laboratories) for 1 hour to ensure blockage of nonspecific sites 
followed by one hour at room temperature or overnight at 4oC incubation with anti-c-kit 
(1:50; Santa Cruz), or anti-MLA-CD63 (1:500; Bios) rabbit monoclonal antibodies diluted 
in 10% NGS. Sections were then washed and incubated for 1 hour with secondary 
antibody goat anti-rabbit Alexa Fluor 568 for c-kit and 660 for CD63 at a concentration 
of 1:20 diluted in 1x PBS. Total nuclei were detected by mounting each section with 
Antifade Vectashield medium containing 4’,6-diamino-2-phenylindole (DAPI; Vector 
Laboratories). Olympus and confocal fluorescence microscopes were used to visualize 
and quantify CD63+ve/c-kit+ve cells over total nuclei. Four representative areas per 
section were taken and quantified using Image J software. Data is presented as % of 
CD63+ve/c-kit+ve cells/total DAPI. 
Immunostaining Determination of CD63+ve/c-kit+ve CSCs Differentiation. 
To verify whether ES-TIMP-1CM and TIMP-1 treatments can trigger CSC 
differentiation into cardiac myocytes (CM), vascular smooth muscle (VSM) and 
endothelial cells (ECs) in the MI heart, previously double stained CD63+ve/c-kit+ve cells 
were triple stained with either  sarcomeric (Src) α-actin, smooth muscle (SM) α-actin, or 
CD31, respectively (11; 29; 30).  After 1 hour incubation in NGS, sections were 
incubated with 1:25 dilution of rabbit anti-CD31 monoclonal antibody (Santa Cruz 
Biotechnologies, Santa Cruz, CA) prepared in 10% NGS, followed by FITC-conjugated 
goat anti-rabbit IgG secondary antibodies (Invitrogen) diluted at 1:50 in PBS for 60 
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minutes. For both Src and SM α-actin staining, mouse anti-mouse kit (MOM, Vector 
Laboratories) was used. In brief, sections were incubated for 1 hour in MOM blocking 
reagent followed by 5 minutes in protein working solution (PWS) provided in the kit. 
Next, anti-SM and anti-Src α-actin antibodies (1:50 and 1:100 respectively, Sigma) were 
diluted in PWS and exposed on the top of the sections for 30 min followed by IgG 
antibody and fluorescein avidin solution for 5 and 10 min each.  
Finally, triple stained sections were mounted with Vectashield antifade medium 
containing DAPI (Vector Laboratories) for nuclear visualization.  Four representative 
images per slide were taken using Olympus and confocal microscopes and Image J 
software was used to quantify cardiac cell differentiation using these formulas: % CM 
differentiation = triple Src α-actin+ve/c-kit+ve/CD63+ve cells over total Src α-actin cells x 
100. % VSM differentiation = triple SM α-actin+ve/c-kit+ve/CD63+ve cells over total 
vascular nuclei x 100. % ECs differentiation = triple CD31+ve/c-kit+ve/CD63+ve cells over 
total vascular nuclei x 100. Of note, representative pictures in Figure 6 were taken from 
the peri-infarct zone of the heart where we localized CSCs differentiating into cardiac 
myocytes. 
Real-Time PCR for CD63 and TIMP-1 mRNAs 
Total RNA was extracted using TRI® reagent protocol (Cat # T9424; Sigma 
Aldrich). In brief, heart pieces from different study groups were homogenized using 1ml 
TRI reagent in an RNase free environment followed by a separation step in chloroform 
and RNA precipitation in isopropyl alcohol. RNA purity and concentration was verified 
using spectrophotometer analysis from absorbance readings of 260 and 280nm. An 
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absorbance ratio of A260/A280 ranging between 1.8 to 2.0 was considered pure. cDNA 
was synthesized from 1 μg total RNA using Superscript II reverse transcriptase and 
random primers (Bio-Rad). Next, Real-time quantitative PCR was performed using a 
CFX96™ Real-Time System (Bio Rad). Supermix 2X; Life Technologies containing 
FAM fluorescent dye and dNTPs in a reaction buffer was added to the reaction mixture 
containing cDNA template, forward, and reverse primers.  CD63, TIMP-1 and GAPDH 
primer assays were purchased from Life Technologies. The following cycling conditions 
were used: 95˚C for 5 min followed by 35 amplification cycles at 95˚C to denature for 15 
seconds and 60˚C for combined annealing/extension for 60 seconds.  The relative fold 
expression of CD63 and TIMP-1 in each group was normalized against GAPDH and 
plotted. 
Western Blots for CD63, β-catenin and phospho-β-catenin Proteins 
To determine the effect of TIMP-1 on CD63/β-catenin pathway, protein level was 
measured on heart homogenates taken from all treatment groups and both mouse 
strains using SDS-PAGE. In brief, an equal amount of protein (100ug) was loaded on a 
10% polyacrylamide gel and subjected to electrophoresis at 150V for 1 hour. The gel 
was then transferred for 45 min to a polyvinylidene fluoride membrane (PVDF; BioRad) 
presoaked in methanol and transfer buffer using a semi-dry Immuno-Blot (Bio-Rad) at 
15V current. The membranes were then blocked with 5% skim milk for 1 hour and 
incubated with primary rabbit antibodies (CD63/MLA1; cat # ABIN687742, Antibodies), 
(β-catenin (6B3) ; cat # 9582, and phospho-β-catenin (Ser33/37/Thr41; cat # 9561, Cell 
signaling) and (β-actin; cat # 4967L from Cell Signaling) for one hour on an orbital 
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shaker at room temperature or at 4oC overnight. Membranes were then incubated with 
anti-rabbit IgG horseradish peroxidase secondary antibody (Cat # 7074S; Cell 
Signaling) for one hour, and blots were detected with Pierce® ECL Western Blotting 
Substrate (Thermo Scientific) (22). 
Statistical Analysis 
All data presented in this study were subjected to statistical analysis using 
SigmaStat 3.5 software. One-way analysis of variance (ANOVA) was run for all 
experiments followed by Tukey test and statistical results were presented as a mean ± 
standard error of the mean (SEM). The difference between two study groups was 
considered statistically significant if the P<0.05. 
Results 
ES-TIMP-1-CM and TIMP-1 Enhance Endogenous CD63+ve/c-kit+ve CSCs 
Proliferation in the Infarcted Myocardium 
The effect of transplanted ES-TIMP-1-CM and TIMP-1 on proliferation of 
endogenous CD63+ve/c-kit+ve CSCs was examined in the infarcted TIMP-1 KO and 
C57BL/6 hearts. Our c-kit cell specific staining combined with CD63 confirms that 
following intramyocardial delivery of ES-TIMP-1-CM and TIMP-1, percent of CD63+ve/c-
kit+ve CSCs significantly increases (p<0.05, ES-TIMP-1-CM: 2.05%±0.33% and TIMP-1: 
1.46%±0.14%) compared with (Sham: 0.48%±0.11% and MI+CC: 1.14%±0.12%) in 
C57BL/6 mice. TIMP-1 KO mice showed similar pattern but with lower ratios (p<0.05, 
ES-TIMP-1-CM 1.52%±0.24% and TIMP-1: 0.86%±0.1%) compared with (Sham: 
0.29%±0.08% and MI+CC: 0.53%±0.05%) (Figure 5).   
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ES-TIMP-1-CM and TIMP-1 Enhance Endogenous CD63+ve/c-kit+ve CSCs 
Differentiation into CMs, VSMs, and ECs in the Infarcted Myocardium 
The effect of transplanted ES-TIMP-1-CM and TIMP-1 on endogenous 
CD63+ve/c-kit+ve CSCs differentiation into CM, VSM, and ECs was examined in the 
infarcted TIMP-1 KO and C57BL/6 hearts. Triple immunostaining targeting newly 
differentiated CMs from CSCs expressing c-kit, CD63 and Src α-actin was performed. 
Our quantitative data revealed no significant alteration in cardiac myocyte differentiation 
in MI and MI+ESCM treatment compared to control in both TIMP-1 KO and C57BL/6 
mice, while enhanced cardiac myocyte differentiation was observed following ES-TIMP-
1-CM and TIMP-1 treatments relative to controls (p<0.05, ES-TIMP-1-CM; 
24.72%±1.32% and TIMP-1; 22.91%±1.03%) against (Sham; 6.93%±0.59%, MI+CC; 
8.91%±0.75%, and ESCM; 10.18%±0.82%) in C57BL/6 and (p<0.05, ES-TIMP-1-CM; 
14.72%±0.71% and TIMP-1; 11.35%±0.86%) against (Sham; 4.35%±0.64%, MI+CC; 
4.36%±0.35%, and ESCM; 6.48%±1.65%) in TIMP-1 KO mice (Figure 6). 
One of the major cardiac cell types lost during a myocardial event are VSM cells, 
which make up cardiac vasculature (29). We aimed at investigating the ability of ES-
TIMP-1-CM or TIMP-1 to promote their regeneration from CD63+ve/c-kit+ve CSCs using a 
triple immunostaining targeting newly differentiating CSCs that express three markers; 
c-kit, CD63 and SM-α-actin (Figure 7). C57BL/6 data revealed decreased sm-α-actin 
cells in MI+CC group compared to control animals, although not significant (MI+CC; 
5.81%±1.59% vs Sham; 8.78%±1.77%). Conversely, TIMP-1 KO animals showed a 
slight increase in VSMs differentiation in MI+CC and ESCM against sham animals, with 
no significance (MI+CC; 3.14%±0.46%, and ESCM; 3.36%±0.21% against Sham; 
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1.69%±0.22%). ES-TIMP-1-CM and TIMP-1 treatments both significantly (P<0.05) 
increased smooth muscle differentiation compared to MI+CC and Sham groups in both 
strains (p<0.05, ES-TIMP-1-CM; 23.47%±5.30% and TIMP-1; 19.13%±2.66%) in 
C57BL/6 and (p<0.05, ES-TIMP-1-CM; 7.17%±1.34% and TIMP-1; 5.43%±0.28%) in 
TIMP-1 KO mice against controls (Figure 7C). 
Endothelial cells are important components of cardiac vasculature (29). Thus, we 
aimed at analyzing their regeneration rate from CD63+ve/c-kit+ve CSCs in the same 
aforementioned conditions. A triple immunostaining targeting newly differentiating CSCs 
expressing c-kit, CD63 and CD31 was performed.  C57BL/6 data revealed significant 
depletion of CD63+ve/c-kit+ve CSCs positive for CD31 marker in MI+CC compared to 
Sham (P<0.05, MI+CC; 4.99%±0.3% vs Sham; 6.91%±0.64%). This decrease was 
significantly (p<0.05) reverted by ESCM, ES-TIMP-1-CM and TIMP-1 treatments 
(P<0.05, ESCM; 7.86%±0.1%, ES-TIMP-1-CM; 11.32%0.42% and TIMP-1; 
10.20%±0.47%). Of note, ES-TIMP-1-CM treatment showed the strongest effect on 
endothelial cell differentiation when compared to sham, MI+CC and ESCM groups. 
TIMP-1 KO data demonstrated no significant change in MI+CC and ESCM groups 
compared to Sham; however, ES-TIMP-1-CM and TIMP-1 significantly increased  ratios 
of CD63+ve/c-kit+ve CSCs differentiating into ECs compared to MI+CC and Sham groups 
(P<0.05, ES-TIMP-1-CM; 10.78%±0.92% and TIMP-1; 9.03%±0.51% vs MI+CC; 
5.65%±0.43% and Sham; 5.55%±0.39%) (Figure 8C). Taken all together, differentiation 
data demonstrate ratios of CD63+ve/c-kit+ve cells positive for CM, VSM, and ECs markers 
are significantly elevated following ES-TIMP-1-CM and TIMP-1 treatments in both 
C57BL/6 and TIMP-1 KO mice compared to their controls, suggesting TIMP-1 may have 
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activated endogenous CD63+ve/c-kit+ve CSCs and enhanced their differentiation into 
CMs, VSMs and ECs in both C57BL/6 and TIMP-1 KO mice (Figure 6-8). 
Representative confocal images demonstrating c-kit/CD63+ CSCs differentiation 
into CMs, VSMs, and ECs are shown in Figure 6, 7 and 8 respectively. In each figure, 
panel A represents C57BL/6 representative figures and panel B depicts TIMP-1 KO 
representative images.  Each panel demonstrates CD63+ve cells in purple (a,f,k,p and 
u), c-kit +ve in red (b,g,l,q and v), Src-α-actin, SM or CD31+ve in green (c,h,m,r and w), 
total nuclei in blue (d,i,n,s and x), and merged images (e,j,o,t, and y). Enlarged images 
of triple stained cells are depicted at the margin of merged images (Figures 6-8).  
Effect of ES-TIMP-1-CM and TIMP-1 on Endogenous TIMP-1 and CD63 mRNAs 
Expression 
 To determine effect of ES-TIMP-1-CM and TIMP-1 delivery on endogenous 
TIMP-1 and CD63 expression, we performed RT-PCR analysis for both mRNAs on 
heart tissue specimens collected from TIMP-1 KO and C57BL/6 animals.  RT-PCR data 
shows near null expression of TIMP-1 mRNA in TIMP-1 KO mice compared to wild type 
(Figure 9A). In parallel, levels of CD63 mRNA significantly dropped in the TIMP-1 
deficient mice compared to C57BL/6 (p<0.05, TIMP-1 KO; 0.05±0.01 vs C57BL/6; 
1±0.0), suggesting a strong correlation between TIMP-1 and CD63 expression in the 
heart (Figure 9B). Next, we compared expression levels of TIMP-1 and CD63 following 
MI and exogenous delivery of ESCM, TIMP-1 and ES-TIMP-1-CM treatments.   Our 
data show no effect of any treatments on TIMP-1 mRNA levels in TIMP-1 KO animals. 
However, C57BL/6 mice showed a noticeable decrease in TIMP-1 expression in MI+CC 
group followed by 2 to 4 fold increase upon ES-TIMP-1-CM and TIMP-1 treatments, 
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respectively (Figure 9C). Next, CD63 mRNA data demonstrate a slight decrease in 
CD63 mRNA expression following MI+CC and ESCM treatment; however, no 
significance was achieved relative to sham group. ES-TIMP-1-CM and TIMP-1 treated 
C57BL/6 mice induced 4 and 2.5 fold increase in CD63 expression compared to MI+CC 
and sham C57BL/6 animals. Ratios of CD63 in TIMP-1 KO animals followed the same 
trend described in C57BL/6 mice; however, at much lower ratios (TIMP-1 KO; ES-TIMP-
1-CM; 0.07±0.03 and TIMP-1; 0.07±0.04) vs (C57BL/6 ES-TIMP-1-CM; 3.98±0.92 and 
TIMP-1; 2.21±0.6) (Figure 9D).  
Mechanism of TIMP-1 Mediated CD63+ve/c-kit+ve CSCs Regeneration in the 
Infarcted Myocardium 
 We compared the effect of TIMP-1 delivery on CD63, phospho (P), and total β-
catenin proteins on heart homogenates (Figure 10). Western blot results on TIMP-1 KO 
mice showed significantly (p<0.05) decreased CD63 levels in MI+CC and MI-ESCM 
groups compared to control. This decrease was drastically (p<0.05) reversed in ES-
TIMP-1-CM and TIMP-1 treatments (Figure 10D). C57BL/6 mice showed a slight 
decrease in CD63 levels in MI+CC group against control; however, no significance was 
achieved. Additionally, ESCM and TIMP-1 treatments slightly increased CD63 
expression without reaching significance. Nonetheless, ES-TIMP-1-CM treatment 
showed a strong increase (p<0.05) in CD63 levels (Figure 10A). Next, we measured 
total β-catenin protein levels (Figure 10B and E). TIMP-1 KO data showed a significant 
decrease in β-catenin protein in MI+CC and ESCM groups relative to sham, however, 
upon ES-TIMP-1-CM and TIMP-1 treatments, the decrease in β-catenin significantly 
improved compared to MI+CC and MI+ESCM animals (Figure 10E). C57BL/6 western 
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blot analysis revealed no significant change in all study groups except ES-TIMP-1-CM 
which showed significantly (p<0.05) increased β-catenin protein expression as 
compared to sham and MI+CC animals (Figure 10B). Finally, we evaluated the ability of 
exogenous TIMP-1 to activate β-catenin. Densitometry analysis of (P)-β-catenin levels 
in TIMP-1 KO mice demonstrated a drastic decrease (p<0.05) in (P)-β-catenin levels in 
MI+CC and ESCM groups compared to sham; however, ES-TIMP-1-CM and TIMP-1 
treatments largely increased (p<0.05) (P)-β-catenin levels (Figure 10F). C57BL/6 hearts 
showed no significant variation in (P)-β-catenin levels in Sham, MI+CC and MI+ESCM 
animals; however, upon ES-TIMP-1-CM and TIMP-1 treatments, activated (P)-β-catenin 
levels strongly (p<0.05) increased (Figure 10C). Overall, this data suggest ES-TIMP-1-
CM and TIMP-1 delivery activated CD63/β-catenin pathway following MI. 
Discussion 
Stem cell transplantation has largely been utilized as a source for cardiac 
regeneration following MI. These cells include ES, Bone Marrow (BM) derived stem 
cells, hematopoietic stem cells (HSCs), mesenchymal stem cells (MSCs), and umbilical-
cord-blood-derived mesenchymal stem cells (UCB-MSCs) (1; 2). The results from these 
experiments were mitigated by inconsistent cell survival following transplantation and a 
limited trans-differentiation rate given their non-cardiogenic origin (1; 2; 14-16; 18; 19; 
25). CSCs are thus, prime candidates for cardiac transplantation given their cardiac 
differentiation potential. Published work demonstrated intramyocardial delivery of 
cardiac progenitor cells (CPCs) to the injured rat myocardium differentiate into cardiac 
myocytes and vascular cells (24). Activation of endogenous CSCs was additionally 
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suggested to occur through paracrine factors released by transplanted CPCs; however, 
the nature of these factors was yet to be determined.  
We previously investigated the ability of ES over-expressing TIMP-1 cells to 
regenerate the lost myocardium in the murine model for MI (11). Data collected from 
this study demonstrated enhanced cardiac regeneration regardless of the low 
engraftment rate of transplanted cells.  We therefore hypothesized that TIMP-1 released 
by transplanted ES cells might target a subset of endogenous CSCs which express 
TIMP-1 receptor (CD63) and trigger their differentiation into the three main cardiac 
populations; cardiac myocytes, smooth muscle, and endothelial cells.  
To address this hypothesis, we performed MI surgery on TIMP-1 KO and 
C57BL/6 mice followed by intramyocardial delivery of ESCM, ES-TIMP-1-CM or 
recombinant TIMP-1 protein. ESCM, TIMP-1, and ES-TIMP-1-CM groups were 
performed to compare the effect of factors released by stem cells, TIMP-1, or both 
respectively. We stipulated that TIMP-1 alone would be sufficient to activate CD63+ve/c-
kit+ve CSCs and regenerate the damaged myocardium. Our data indeed demonstrated 
that ESCM performed less than TIMP-1 and ES-TIMP-1-CM did not provide a better 
outcome when compared to TIMP-1 alone, demonstrating that other factors do not play 
a role in CD63+ve/c-kit+ve activation. Our collected data demonstrate in vivo delivery of 
ES-TIMP-1-CM or TIMP-1 equivalently: 1) enhance CD63+ve/c-kit+ve CSCs proliferation 
and differentiation into cardiac myocytes, endothelial and vascular smooth muscle cells, 
2) promote additional CD63 expression in the heart, 3) up regulate phospho and total β-
catenin expression. This study additionally demonstrates that TIMP-1 deletion 
significantly reduces the number of CD63+ve/c-kit+ve CSCs population in the heart and 
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exogenous delivery of TIMP-1 is sufficient to replenish their pool. We believe that 
endogenous TIMP-1 triggers expression of CD63 receptor on c-kit positive cells as 
demonstrated by the dramatic decrease in CD63 mRNA expression in TIMP-1 KO 
hearts. Furthermore, our data shows TIMP-1 enhances CD63+ve/c-kit+ve CSCs 
proliferation which explains the decreased number of CD63+ve/c-kit+ve cells in the heart 
of TIMP-1 KO vs. C57 control animals. This finding is in accordance with prior study 
suggesting paracrine factors released by transplanted CPCs activate endogenous 
CPCs (64), and previously published data suggesting TIMP-1 released by stem cells 
mediates human mesenchymal stem cell (hMSC) proliferation and differentiation (13).  
Next, we provide evidence that CD63+ve/c-kit+ve CSC activation is mediated 
through CD63/β-catenin pathway as suggested by increased CD63, β-catenin and 
phospho-β-catenin expression in MI hearts treated with ES-TIMP-1-CM and TIMP-1. 
Enhancement of β-catenin and phospho-β-catenin expression in C57BL/6 infarcted 
heart mice after ES-TIMP-1-CM and TIMP-1 treatment and/or their rescuing after these 
same interventions in TIMP-1 KO mice might be explained by activation of CD63 which 
induces dephosphorylation of Axin complex preventing β-catenin ubiquitination and 
degradation. Additionally, released β-catenin is subsequently activated by 
phosphorylation prior to nucleus translocation.  We additionally stipulate that 
endogenous TIMP-1 triggers expression of additional CD63 receptor on c-kit positive 
cells by activating CD63/β-catenin pathway in a positive feedback loop. Furthermore, 
our data show TIMP-1 enhances CD63+ve/c-kit+ve CSCs proliferation which additionally 
explains the increased amount of available CD63 mRNA as well as the dramatic 
decrease in CD63 mRNA expression in TIMP-1 KO hearts.  
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 Activated CD63/β-catenin pathway and subsequent enhanced cardiac 
differentiation following TIMP-1 administration contradicts published work attesting 
TIMP-1 enhances cell proliferation but hinders cardiac differentiation in hMSCs through 
blockage of the CD63/β-catenin pathway (8). Nonetheless, our results are in 
accordance with multiple other studies  demonstrating ability of ES cells to differentiate 
into cardiac cells through activation of β-catenin pathway and subsequent expression of 
cardiac genes, such as Nkx2.5, β-myosin heavy chain (β-MHC) and cardiac troponin T 
(cTnT) (17; 20).   
In the present study, we choose to identify c-kit+ve CSCs because they represent 
the most prevalent and extensively characterized subset of CSCs pool. Other CSCs 
involve side population (SP) cells, cardiac progenitor cells (CPCs), Sca-1+ve cells, cardio 
sphere cells and Isl1+ve cells, which are less abundant and poorly characterized (2). It is 
therefore, imperative to identify the relative contribution of CD63+ve CSCs that are not c-
kit+ve. CD63 was also shown to be expressed in adult cardiac myocytes and vascular 
endothelial cells (13). These cells might have differentiated from CD63+ve/c-kit+ve CSC 
origin and kept CD63 marker expression when fully differentiated. Furthermore, we and 
others have previously demonstrated that TIMP-1 reduces cardiac apoptosis, fibrosis 
and enhances cell proliferation following MI; however, not much is known about the 
molecular mechanism mediating this protective effect and whether ES-TIMP-1-CM or 
ESCM would provide a better protection (11). In the current paper we stipulate that the 
anti-apoptotic, anti-fibrotic and proliferative role of TIMP-1 in the heart is most likely 
mediated through CD63 receptor maintained on these cells. Additional protective 
54 
 
mechanisms mediated by other factors present in the conditioned media are also very 
likely. Nonetheless, future studies are warranted to support or refute this hypothesis.   
In conclusion, our data demonstrate for the first time existence of a unique 
subset of CSCs in the peri-infarct area, double positive for c-kit and CD63 markers. 
These cells can be triggered to differentiate into cardiac cells by exogenous delivery of 
TIMP-1 factor or ES-TIMP-1-CM.  Stimulation of CD63+ve/c-kit+ve CSCs leads to 
enhanced cardiac regeneration. Additionally, we provide evidence that CD63+ve/c-kit+ve 
CSCs activation is mediated through CD63/β-catenin pathway. This paper 
demonstrates for the first time that besides the anti- cardiac remodeling effect of TIMP-
1, this molecule has a strong regenerative potential. This multifaceted characteristic of 
TIMP-1 makes it a suitable candidate for MI patients.   
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Figures 
 
Figure 5. ES-TIMP-1-CM and TIMP-1 Enhance Endogenous CD63+ve/c-kit+ve CSCs 
Proliferation in the Infarcted Myocardium.   A triple immunostaining targeting 
CD63+ve/c-kit+ve CSCs niche and sarcomeric (Src) α-actin (cardiac myocytes marker) 
was performed and representative confocal images are shown in Figure 5A. CD63+ve 
cells are shown in purple (a,f,and k), c-kit +ve in red (b,g and l), Src-α-actin+ve in green 
(d,i and n), total nuclei in blue (c, h and m), and merged images (e,j and o). Scale bar = 
50µm (a-e) and 25µm (f-j). Enlarged images of double stained cells are depicted in (k-
o). Ratio of double positive CD63+ve/c-kit+ve cells over total DAPI was quantified on 
C57BL/6 and TIMP-1 KO mice and results are plotted in Figure 5B. Data was collected 
from n=5 animals per group and 1 section per animal.*p<0.05. vs Sham, #p<0.05 vs 
MI+CC and $ p<0.05 vs MI+ESCM. Brackets over each group means the given 
significance above it applies to both strains. 
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Figure 6. ES-TIMP-1-CM and TIMP-1 Enhance Cardiac Myocyte Differentiation of 
CD63+ve/c-kit+ve CSCs in the Infarcted Myocardium.  A triple immunostaining 
targeting newly differentiated CSCs expressing the three markers; c-kit, CD63 and 
sarcomeric (Src) α-actin (cardiac myocytes marker) was performed and representative 
confocal images are shown in Figure 6A for C57BL/6 and Figure 6B for TIMP-1 KO. 
CD63+ve cells are shown in purple (a,f,k,p and u), c-kit +ve in red (b,g,l,q and v), Src-α-
actin +ve in green (c,h,m,r and w), total nuclei in blue (d,i,n,s and x), and merged 
images (e,j,o,t, and y). Scale bar = 25µm. Enlarged images of triple stained cells are 
depicted at the margin of merged images. Figure 6C shows % CD63+ve/c-kit+ve CSCs 
positive for sarcomeric α-actin. Data was collected from n=5 animals per group and 1 
section per animal.*p<0.05. vs Sham, #p<0.05 vs MI+CC and $ p<0.05 vs MI+ESCM. 
Brackets over each group means the given significance above it applies to both strains. 
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Figure 7. ES-TIMP-1-CM and TIMP-1 Enhance Smooth Muscle Differentiation of 
CD63+ve/c-kit+ve CSCs in the Infarcted Myocardium.  A triple immunostaining 
targeting newly differentiated CSCs expressing the three markers, c-kit, CD63 and 
smooth muscle (SM) α-actin was performed. Representative confocal images are 
shown in Figure 7A for C57BL/6 and Figure 7B for TIMP-1 KO. CD63+ve cells are shown 
in purple (a,f,k,p and u), c-kit +ve in red (b,g,l,q and v), Sm-α-actin +ve in green (c,h,m,r 
and w), total nuclei in blue (d,i,n,s and x), and merged images (e,j,o,t, and y). Scale bar 
= 25µm. Enlarged images of triple stained cells are depicted at the margin of merged 
images. Histogram 7C shows quantitative data of % CD63+ve/c-kit+ve also positive for 
smooth muscle cell marker. Data was collected from n=5 animals per group and 1 to 2 
section per animal. *p<0.05. vs Sham, #p<0.05 vs MI+CC and $ p<0.05 vs MI+ESCM. 
Brackets over each group means the given significance above it applies to both strains. 
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Figure 8. ES-TIMP-1-CM and TIMP-1 Enhance Endothelial Cell Differentiation of 
CD63+ve/c-kit+ve CSCs in the Infarcted Myocardium.  Figure 8 depicts confocal 
representative images taken from a triple immunostaining targeting newly differentiated 
CSCs expressing the three markers: c-kit, CD63 and CD31. Figure 8A represents 
C57BL/6 experiment and Figure 8B for TIMP-1 KO. CD63+ve cells are shown in purple 
(a,f,k,p and u), c-kit +ve in red (b,g,l,q and v), CD31+ve in green (c,h,m,r and w), total 
nuclei in blue (d,i,n,s and x), and merged images (e,j,o,t, and y). Scale bar =25µm. 
Enlarged images of triple stained cells are depicted at the margin of merged images. 
Histogram 8C shows quantitative data of % CD63+ve/c-kit+ve CSCs also positive for 
endothelial cell marker. Data was collected from n=5 animal per group and 1 to 2 
section per animal. *p<0.05. Vs Sham, #p<0.05 vs MI+CC and $ p<0.05 vs MI+ESCM. 
Brackets over each group means the given significance above it applies to both strains. 
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Figure 9. Effect of ES-TIMP-1-CM and TIMP-1 on Endogenous TIMP-1 and CD63 
mRNAs Expression in the Infarcted Myocardium.  CD63 and TIMP-1 mRNA levels 
were measured on heart tissue specimens collected from C57BL/6 and TIMP-1 KO 
control animals. Quantitative RT-PCR relative fold change data for TIMP-1 mRNA is 
plotted in Figure 9A and CD63 mRNA in Figure 9B. Histograms 9C and 9D demonstrate 
levels of these two molecules in MI+CC and MI plus exogenous delivery of ESCM, 
TIMP-1 and ES-TIMP-1-CM treatments in both animal models. Data was collected from 
n=5 samples per group for TIMP-1 and n=6 to 7 for CD63 measurements.*p<0.05. vs 
Sham, #p<0.05 vs MI+CC and $ p<0.05 vs MI+ESCM. Brackets over each group 
means the given significance above it applies to both strains. 
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Figure 10. Mechanism of TIMP-1 Mediated CD63+ve/c-kit+ve CSCs Regeneration in 
the Infarcted Myocardium.  Figure 10 depicts densitometry analysis of western blots 
for CD63, activated phospho (p) and total β-catenin proteins measured on heart 
homogenates from both C57BL/6 mice (Figures 10A-C) and TIMP-1 KO mice (Figure 
10D-F). Representative blots for each histogram are also included above each 
corresponding histogram. Data was collected from n=4-6 samples per group. *p<0.05 vs 
Sham, #p<0.05 vs MI+CC and $ p<0.05 vs MI+ESCM. Brackets over each group 
means the given significance above it applies to both strains. 
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CHAPTER FOUR: TIMP-1 AND ES CELLS OVEREXPRESSING TIMP-1 CONDITION 
MEDIA BLUNT ADVERSE CARDIAC REMODELING FOLLOWING MYOCARDIAL 
INFARCTION  
Abstract 
Transplanted mouse ES cells overexpressing tissue inhibitor of 
metalloproteinase-1 (TIMP-1) in the infarcted myocardium demonstrated inhibited 
adverse cardiac remodeling and improved cardiac function. However, whether these 
beneficial effects are provided by transplanted cells or TIMP-1 factor released in the 
conditioned media (CM) was previously unknown. Therefore, we hypothesized that 
intramyocardial delivery of ES-TIMP-1-conditioned medium (CM) or TIMP-1, following 
myocardial infarction (MI), inhibit cardiac apoptosis and fibrosis and resume contractile 
function.  Accordingly, age matched C57BL/6 and TIMP-1 KO mice were subjected to 
coronary artery ligation followed by intramyocardial delivery of 20µl of culture media 
(CC), ESCM, ES-TIMP-1-CM or TIMP-1. TUNEL staining, Caspase-3 activity ELISA, 
Masson’s Trichrome, and echocardiography analysis were used to assess apoptosis, 
fibrosis, and heart function respectively. Two weeks post-MI, ES-TIMP-1-CM and TIMP-
1 significantly (p<0.05) reduced overall cardiac apoptosis as well as Caspase-3 
mediated cardiac myocytes cell death compared with ESCM group in both TIMP-1 KO 
and control animals. Infarct size, interstitial and vascular fibrosis were significantly 
(p<0.05) decreased in the ES-TIMP-1-CM and TIMP-1 groups compared to controls. 
Furthermore, we demonstrated that TIMP-1 factor alone is sufficient to significantly 
resorb cardiac remodeling in both TIMP-1 KO and control animals regardless of the 
severity of damage. Finally, echocardiography data showed fractional shortening and 
ejection fraction were significantly (p<0.05) improved in the ES-TIMP-1-CM and TIMP-1 
67 
 
groups in both strains. Our data suggest that ES-TIMP-1-CM or TIMP-1 alone provide 
an equivalent protection against adverse cardiac remodeling and shall be considered as 
potential therapeutic tools for MI patients.    
Keywords:  Myocardial Infarction, TIMP-1, Apoptosis, Fibrosis, Cardiac Function. 
Introduction 
Adverse cardiac remodeling is the process by which the myocardium size, 
conduction and function are altered as a result of myocardial infarction (MI), 
myocarditis, or idiopathic dilated cardiomyopathy (1). The gross pathological changes 
involved in cardiac remodeling are; massive cardiac myocyte cell loss through 
apoptosis, increased infiltration of collagen fibers throughout the infarct zone and 
cardiac myocyte hypertrophy, leading to deregulated contractile function (1-3). Cardiac 
myocyte apoptosis following MI activates cardiac fibroblasts, which are the main cellular 
modulators of cardiac fibrosis. They control extracellular matrix (ECM) turn over through 
secretion of matrix metalloproteinases (MMPs), otherwise called Matrixins, and their 
direct inhibitors; tissue inhibitor of metalloproteinases (TIMPs) (3-6). The main function 
of matrixins is the degradation and removal of ECM molecules as well as stimulation of 
collagen I, III and IV production from fibroblasts (7; 8). Following MI, upregulation of 
MMP2 and MMP9 has been correlated with aberrant collagen build up in the infarct area 
(7; 8). Concurrently, levels of TIMP-1 have been shown to be significantly down-
regulated post MI (4). Furthermore, published data demonstrated TIMP-1 
downregulation correlates with exacerbated cardiac myocyte apoptosis and increased 
fibrotic tissue (7).  Increased cardiac myocyte death and accumulated collagen 
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deposition within the infarct zone leads to ventricular wall stiffening resulting in impaired 
systolic and diastolic functions (1; 4; 7).  
Up regulation of TIMP-1 in the MI heart by direct delivery of TIMP-1 protein or 
vector to the peri-infarct area has demonstrated decreased overall infarct size, infiltrated 
fibrosis and cardiac myocyte apoptosis which positively impacted contractile function 
(9). Similarly, pharmacological inhibition of MMPs using PD-166793 compound was 
able to rescue the MI heart (7). Others have investigated stem cell transplantation as a 
way to replace apoptotic cardiac myocytes and vasculature in different animal models 
for MI (4; 8; 10; 11). Stem cells have the potential to regenerate the myocardium and 
consequently prevent fibrotic tissue accumulation. However, their survival rate in the 
host myocardium is very timid which greatly limits their differentiation potential in vivo 
(12; 13). Previously, we have generated embryonic stem (ES) cells overexpressing 
TIMP-1 factor (ES-TIMP-1 cells). When transplanted to the MI heart, these cells 
demonstrated limited engraftment to the host myocardium; however, collected data 
showed a significant decrease in cardiac remodeling parameters as well as improved 
functional capacity of the heart (4).  Therefore we hypothesized that TIMP-1 released by 
ES-TIMP-1 cells provided the aforementioned protective effect to the heart. 
Furthermore, ES cells are known to secrete other beneficial factors such as; Insulin 
Growth Factor (IGF), Hepatic Growth Factor (HGF), Stem Cell Factor (SCF), and 
Vascular Endothelial Growth Factor (VEGF), all of which regulate cell proliferation and 
angiogenesis and might be aiding TIMP-1 in blunting left ventricular remodeling (14-16). 
In the present study, we compared the anti-cardiac remodeling effect of direct 
transplantation of TIMP-1 protein, ES condition media (CM), which contains factors 
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released by ES cells, and ES-TIMP-1-CM in the MI heart of both C57BL/6 and TIMP-1 
KO mice. Our study will provide evidence that ES cells released factors combined with 
TIMP-1 or TIMP-1 alone provide an equivalent protection against adverse cardiac 
remodeling and shall be considered as potential therapeutic tools for MI patients.    
Materials and Methods 
Condition Media Preparation from ES and ES-TIMP-1 Cells 
Embryonic Stem (CGR8) cells overexpressing TIMP-1 factor (ES-TIMP-1 cells) 
were generated by transfection of pTurboFP635-C (Homemade) vector encoding red 
fluorescent protein (RFP), mouse TIMP-1 cDNAs and neomycin resistance gene. 
Transfection was carried out using Lipofectamine 2000 (Invitrogen). Resulting cells 
were selected by treatment with G418 antibiotic (Invitrogen) (4). Condition media 
preparation from both cell lines was carried out as previously detailed (4). Briefly, ES 
and ES-TIMP1 cells were cultured till confluence in presence of DMEM containing LIF, 
sodium pyruvate, glutamine, β-mercaptoethanol, penicillin-streptomycin, nonessential 
amino acids, and 15% ES cell-qualified fetal bovine serum (Invitrogen). LIF was then 
removed and cells were cultured for 48 hours on gelatin coated plates supplemented 
with cell culture media (CC). Following the 48 hours incubation, cell media containing 
factors released from ES and ES-TIMP-1 cells were collected in separate tubes, labeled 
ESCM and ES-TIMP-1-CM respectively and saved for future use in -20oC. 
TIMP-1 Preparation 
Recombinant mouse TIMP-1 (R&D; cat # 980-MT) lyophilizat was reconstituted 
in sterile water containing  a mixture of Tris (50mM), Cacl2 (10mM), NaCl (150mM), and 
70 
 
Brij35 (0.05%) to a concentration of 100ug/ml. aliquots of 100µl volumes were made and 
stored in -20oC. 
Myocardial Infarction and Treatment Administration 
All animal procedure detailed hereafter was approved by the University of Central 
Florida (UCF) Institutional Animal Care and Use Committee (IACUC). C57BL/6 and 
TIMP-1 KO on C57BL/6 background (B6.129S4-Timp1tm1Pds/J; Jackson laboratories; 
Cat# 006243) were bred at the UCF’s Transgenic Animal Facility (TAF) until 8 to 10 
weeks old. Next, equal number of males and females from both strains were separated 
into five study groups; Sham (n=8), MI+Culture Media (CC; n=8), MI+ESCM (n=8), 
MI+ES-TIMP-1-CM (n=8) and MI+TIMP-1 (n=8), where “n” is the number of animals per 
study group. Left anterior descending (LAD) coronary artery ligation surgery was 
performed on the last four groups following previously reported procedure (17-19). In 
brief, animals were sedated with 4% isoflurane and 2% oxygen provided through an 
endotracheal intubation system (Minivent Type 845; Harvard Apparatus). 
Buprenorphine intra-muscular injection (0.5mg/kg) was also given to animals prior to 
surgery and 2-3 hours post-surgery to aid in pain relief. As part of the pre-operative 
procedure, the chest was shaved, alcohol sterilized and covered with betadine. A 
thoracotomy was then performed, the heart was exposed and the LAD ligated using a 
surgical suture needle (Monofilament polypropylene non-absorbable suture, 7/0; cat # 
8703P; CP Medical, Portland). Artery ligation was confirmed when a bleaching area 
around the ligation site occurs following ligation. 20µl of CC, ESCM, ES-TIMP1-CM or 
TIMP-1 (200ug/kg of body weight) was injected at two peri-infarct sites using a 700 
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Series MICROTITER Syringe supplemented with a gauge floating needle (Hamilton CO, 
Nevada). Sham operated animals were put under the same stress but the ligation was 
kept loose. Following treatments, thoracotomy was sutured back up and the mice were 
allowed to recover under strict supervision. Two weeks post-surgery, mice were 
sedated with Isoflurane overdose and sacrificed by cervical dislocation.  
Tissue Embedding and Preparation of Paraffin Sections  
Mice hearts were excised two weeks following surgery, washed in 1 X PBS and 
the bottom portion containing both ventricles was fixed in paraformaldehyde (PFA 4%) 
(17-19). PFA stored hearts were dehydrated by exposure to serial concentrations of 
Ethanol and embedded in paraffin. 5µm thickness sections were made using a tissue 
processor than placed on microscope slides (Fisher scientific). The wax remaining on 
the tissue section was melted down by incubating section in 60oC for 30 minutes. Prior 
to any staining, deparaffinization and rehydratation of the tissue specimens was 
achieved by sequential dipping in xylene and descending concentrations of alcohol. 
Tissues were finally washed in distilled water and phosphate-buffered saline (PBS 1x) 
for an additional 5 minutes.  
Determination of Infarct size 
A standard Masson's trichrome protocol was performed on tissue sections to 
detect collagen deposition in the MI area (4). In brief, deparaffinized and rehydrated 
sections were successively immersed into Weigert iron hematoxylin, acid fuchsin, 
phosphomolybdic-phosphotungstic acid, and aniline blue. Under bright filed Olympus 
microscope, healthy cells stained in pink, nuclei stained in dark purple and collagen 
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deposits stained in bright blue. Whole heart micrographs were taken under 2 X objective 
and Image J software was used to measure the whole heart and the infarct site area.  
Infract size was calculated using this formula: LV infarct area/LV area x 100%.  
Determination of Infiltrated Interstitial and Vascular Fibrosis  
Interstitial fibrosis defined as the amount of collagen infiltrated within the 
interstitial space was detected on previously Masson’s Trichrome stained sections. In 
brief, four to six photomicrographs were taken under 20X bright field light Olympus 
microscope objective and the blue area (collagen) was measured in each photo using 
Image J software. The average of 4 measured areas was taken as representative of the 
section. Seven to eight hearts per group were used for statistical analysis (4). Vascular 
fibrosis was averaged from 6 different vessels per sections using this equation: vascular 
fibrosis/ vessel area x 100% in one to two sections from seven to eight hearts per 
group.  
Determination of Apoptotic Nuclei and Apoptotic Cardiac Myocytes by TUNEL 
Staining 
Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining 
was performed on tissue sections to determine the ratio of apoptotic cells versus total 
viable cells between the different study groups. Briefly, deparaffinized and rehydrated 
heart sections were permeabilized with proteinase K (25 ug/ml in 100mM Tris-HCL), 
then immunostained using TUNEL kit (TMR red; Roche Applied Bio Sciences) which 
stains apoptotic nuclei in red.  For detection of apoptotic cardiac myocytes, previously 
TUNEL stained section were double stained with mouse anti sarcomeric α-actin (Sigma 
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Aldrich) following mouse on mouse protocol (MOM, Vector Laboratories). Succinctly, 
sections were incubated for 1 hour in MOM blocking reagent followed by 5 mins in 
protein working solution (PWS) provided with the kit. Next, sections were incubated for 
30 min with anti sarcomeric α-actin antibody (1:100), followed by 5 mins of IgG antibody 
and 10 mins of Fluorecin avidin solution. Finally, to detect whether cardiac myocytes 
apoptosis was mediated by Caspase-3 cascade, a third staining was performed using 
anti-rabbit polyclonal Caspase-3 primary antibody (1:1000, cell signaling). Hearts were 
incubated overnight with primary antibody followed by anti-rabbit secondary Alexa 660 
(1:50, Invitrogen) for an hour. To detect total nuclei, sections were covered with antifade 
vectashield mounting medium containing 4’,6-diamino-2-phenylindole (DAPI; Vector 
Laboratories). Olympus fluorescence microscope and LEICA laser scanning confocal 
microscope were used to identify triple stained sections and 4 images of randomly 
selected areas per sections were taken under 20X objective. Data per animal was 
obtained by averaging measurements from all four areas. Percent TUNEL positive 
nuclei was measured using the following formula: total positive cells/Total DAPI X100%. 
For Apoptotic cardiac myocytes: double positive cells for Sarcomeric α-actin and 
TUNEL were quantified and divided by total cardiac myocytes number. 1 to 2 sections 
per heart were analyzed and 5 to 6 hearts per group were used for statistical analysis 
(4).  
Caspase-3 Activity Assay 
To verify cardiac apoptosis is mediated by Caspase-3 machinery, heart 
homogenates from all study groups and both strains were assayed with the Caspase-3/ 
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CPP32 colorimetric assay kit (K106-200, Biovision). Briefly, 1:10 dilutions were made 
from homogenates using lysis buffer provided with the kit and protein estimation was 
measured using Bio-Rad protein assay kit. Caspase-3 assay steps were carried out on 
a 96 well plate according to manufacturer’s protocol until detection of blue color 
indicative of presence of active form of the protein. A microtiter plate reader was used to 
measure intensity of the blue color under 400nm to 405nm. Caspase-3 activity graph 
was plotted as arbitrary units (A.U) (4). 
Echocardiography Analysis for Cardiac Function 
To evaluate how ES-TIMP-1-CM and TIMP-1 treatments translate at the 
physiological level, echocardiography analysis was performed on mice hearts at day 14 
post surgery using a Phillips Sonos 5500 Ultrasound system in a similar fashion 
previously reported (17-19). Mice were sedated with 2 to 4% volume of isoflurane and 
2% oxygen delivered via nose cone, their chest hair was removed and the sonogram 
probe was positioned on top of the chest facing the head to record two dimensional (2D) 
images in a long axis projection with a guided M-mode. Three to four 2D images where 
obtained and the left ventricular fractional shortening (%FS) and left ventricular ejection 
fraction (%EF) were recorded.  %EF was calculated using this formula [(left ventricular 
volume at end diastole (EDV) - left ventricular volume at end systole (ESV)/ left 
ventricular volume at end diastole (EDV)]. EDV and ESV were calculated using 
Teichholz formula:  
EDV= [7/ (2.4+LVIDd)].LVIDd3.  
ESV= [7/ (2.4+LVIDs)].LVIDs3. 
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Left ventricular interior diameter during diastole (LVIDd) and left ventricular 
interior diameter during systole (LVIDs) were manually measured on the motion mode 
screen shots taken for each animal. 
Statistical Analysis 
 Data are reported as Means ± SEMs (Standard Error of Mean). Significance was 
determined using one-way analysis of variance (ANOVA) performed on SigmaStat3.5 
software followed by Tukey or Bonferroni tests. Difference between two study groups 
was considered statistically significant if p<0.05. 
Results 
ES-TIMP-1-CM and TIMP-1 Blunt Apoptosis in the Infarcted Myocardium  
To demonstrate the anti-apoptotic effect of ES-TIMP-1-CM and TIMP-1 on the 
host myocardium following MI, tissue sections were subjected to TUNEL staining which 
distinguishes apoptotic nuclei with a red color. Quantification of percent apoptotic nuclei 
against total DAPI revealed apoptosis dramatically increases in MI-CC hearts relative to 
control (p<0.05, MI-CC;2.1%±0.3% vs Sham; 0.3%±0.05%) for C57BL/6 and (p<0.05, 
MI-CC; 2.86%±0.4% vs Sham; 0.4%±0.07%) for TIMP-1 KO mice (Figure 11B). 
Importantly, ESCM, ES-TIMP-1-CM and TIMP-1 transplantation significantly mitigated 
apoptosis (p<0.05, ESCM; 0.95%±0.12%, ES-TIMP-1-CM; 0.31%±0.07% and TIMP-1; 
0.71%±0.1%) in C57BL/6 mice and (p<0.05, ESCM; 1.59%±0.2%, ES-TIMP-1-CM; 
0.45%±0.17% and TIMP-1; 0.67%±0.1%) in TIMP-1 KO mice  relative to their respective 
MI-CC groups (Figure 11B).  Notably, although all treatments significantly decreased 
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(p<0.05) apoptosis compared to MI-CC, only ES-TIMP-1-CM and TIMP-1 groups were 
able to decrease it up to Sham levels (Figure 11B). 
Next, we aimed at evaluating whether ES-TIMP-1-CM and TIMP-1 treatments 
were able to blunt Caspase-3 mediated cardiac myocytes apoptosis.  Therefore, a triple 
immunostaining for TUNEL, sarcomeric α-actin and Caspase-3 markers was performed 
on heart sections. Figure 12A depicts confocal representative images obtained from MI-
CC animals from C57BL/6 mice (a-f) and TIMP-1 KO (g-l) demonstrating apoptotic 
nuclei in red (a and g), Caspase-3 positive cells in yellow (b and h), sarcomeric α-actin 
positive cells in green (c and i), and total nuclei in blue (d and j). A merge of four 
stainings is depicted in white (e and k) and enlarged areas from e and k are presented 
in (f) and (l), respectively.   Our quantitative data for percent TUNEL positive cardiac 
myocytes show cardiac myocyte apoptosis significantly elevated following MI (p<0.05, 
MI-CC;2.45%±0.29% vs Sham; 0.36%±0.06%) for C57BL/6 and (p<0.05, MI-CC; 
5.42%±0.68% vs Sham; 0.42%±0.03%) for TIMP-1 KO mice (Figure 12B). However, 
upon treatment with ESCM, ES-TIMP-1-CM or TIMP-1, these ratios significantly 
reduced compared with MI-CC hearts and this regardless of the strain (p<0.05, ESCM; 
1.07%±0.11%, ES-TIMP-1-CM; 0.84%±0.06% and TIMP-1; 0.92%±0.19%) in C57BL/6 
mice and (p<0.05, ESCM; 2.9%±0.3%, ES-TIMP-1-CM; 1.01%±0.14% and TIMP-1; 
1.22%±0.17%) in TIMP-1 KO mice  (Figure 12B). Data additionally show ES-TIMP-1-
CM and TIMP-1 provide the greatest improvement against non-treated MI hearts in 
TIMP-1 KO mice when compared to ESCM treatment, while the three aforementioned 
treatments had similar effects on cardiac myocyte apoptosis in C57BL/6 mice  (Figure 
12B). Interestingly, caspase-3 activity measured on heart homogenates collected from 
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all study groups and both stains revealed similar pattern to cardiac myocyte apoptosis 
(Figure 12C). In brief, data show increased caspase-3 activity in MI-CC animals for both 
strains; however, ES-TIMP-CM and TIMP-1 treatments significantly (p<0.05) reduced its 
activity. Of note, even though ESCM treatment decreases Caspase-3 activity, it did not 
reach significance against MI-CC animals for either strain (Figure 12C).  
Reduced Interstitial and Vascular Fibrosis Following ES-TIMP-1-CM and TIMP-1 
Transplantation in the Infarcted Myocardium 
Masson’s trichrome stained heart sections were used to quantify interstitial and 
vascular fibrosis. Figure 13A depicts interstitial fibrosis (IF) representative images 
obtained from all study groups per strain.  Measured interstitial fibrosis area 
demonstrate a significant (p<0.05) increase in IF area (mm2) following MI in both 
C57BL/6 and TIMP-1 KO animals compared to their respective controls (p<0.05, MI-CC; 
1.04±0.1 vs Sham; 0.03±0.008) for C57BL/6 and (p<0.05, MI-CC; 1.43±0.2 vs Sham; 
0.03±0.01) for TIMP-1 KO mice (Figure 3B). Our data additionally demonstrate 
significantly (p<0.05) decreased interstitial fibrosis following ESCM, ES-TIMP-1-CM and 
TIMP-1 treatments compared to MI-CC hearts. Notably, ES-TIMP-1-CM and TIMP-1 
showed the greatest decrease in IF measurements regardless of the strain when 
compared to ESCM treatment (p<0.05) (Figure 13B).  Next, we quantified accumulated 
vascular fibrosis (VF) and our data revealed significantly increased (p<0.05) collagen 
deposition around vessels in MI-CC animals (Figure 14B). This increase was however, 
significantly blunted with ESCM, ES-TIMP-1CM and TIMP-1 treatments (p<0.05 vs MI-
CC) in both C57BL/6 and TIMP-1 KO animals (Figure 14B). Moreover, ES-TIMP-1-CM 
and TIMP-1 treatments were able to blunt VF and IF in a similar fashion for both strains 
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even though TIMP-1 KO animals demonstrated higher IF and VF measurements 
following MI compared to their C57BL/6 counterparts.  
Reduced Infarct Size Following ES-TIMP-1-CM and TIMP-1 Transplantation in the 
Infarcted Myocardium 
To evaluate the effect of ES-TIMP-1-CM and TIMP-1 treatments on the infarct 
area post MI, heart sections were subjected to Masson’s trichrome staining and whole 
heart images were taken under 2x objective of bright field Olympus microscope. 
Representative whole-heart images depicting infarct size from both strains and all 
corresponding treatment groups are represented in Figure 15A. Quantification analysis 
revealed that the dramatic infarct size induced by MI surgery was significantly blunted 
following transplantation of ESCM, ES-TIMP-1-CM and TIMP-1 (p<0.05, ESCM; 
8.24%±0.92%, ES-TIMP-1-CM; 3.21%±0.6% and TIMP-1; 4.85%±1%) in C57BL/6 mice 
and (p<0.05, ESCM; 9.5%±1.58%, ES-TIMP-1-CM; 4.79%±0.8% and TIMP-1; 
4.25%±0.51%) in TIMP-1 KO mice  relative to their respective MI-CC groups (C57BL/6, 
MI-CC; 14.25%±1.25% and TIMP-1 KO, MI-CC; 17.69%±0.5%) (Figure 15B). ESCM 
treatment alone provided a significant (p<0.05) improvement in infarct size reduction, 
however, to a lower degree compared to the later treatments. More importantly, TIMP-1 
KO animals showed a drastic increase in infarct size compared to their C57BL/6 
counterparts, however, ES-TIMP-1-CM and TIMP-1 treatments were able to significantly 
(p<0.05) resorb the infarct area in a similar fashion for both strains (Figure 15). 
79 
 
Improved Heart Function Following ES-TIMP-1-CM and TIMP-1 Treatments in the 
Infarcted Myocardium 
Cardiac function was measured 14 days after MI procedure. Our data suggest a 
significant improvement in cardiac fractional shortening (FS) following ES-TIMP-1-CM 
and TIMP-1 treatments in C57BL/6 mice (p < 0.05, ES-TIMP-1-CM; 40.89% ± 1.33% 
and TIMP-1; 37.64% ± 0.92% vs MI+CC; 32.35% ± 0.34% and ESCM; 34.55% ± 
1.46%) and TIMP-1 KO mice (p < 0.05, ES-TIMP-1-CM; 38.21% ± 1.67% and TIMP-1; 
36.68% ± 1.13% vs MI+CC; 27.85% ± 1.28% and ESCM; 31.57% ± 1.95%) (Figure 
16B). However, improved function following either ES-TIMP-1-CM or TIMP-1 
transplantation was lower than sham in both TIMP-1 KO (46.89% ± 1.37%) and 
C57BL/6 (51.83% ± 1.34%) groups. We also determined that left ventricular ejection 
fraction (EF) was more significantly impacted in C57BL/6 than TIMP-1 KO hearts 
following MI. However, its levels significantly (p<0.05) increased in the ES-TIMP-1-CM 
(72.59% ± 3.29%) and TIMP-1(69.54% ± 0.52%) compared with MI+CC (59.68% ± 
0.4%) and ESCM (63.45% ± 3.77%) in TIMP-1 KO mice (Figure 16C). Moreover, 
significantly (P<0.05) increased ejection fraction was also observed in the ES-TIMP-1-
CM (83.58% ± 1.34%) and TIMP-1 (69.04% ± 0.56%) groups compared with MI+CC 
(62.30% ± 0.52%) and ESCM (64.1% ± 2.1%) groups in C57BL/6 mice (Figure 16B). 
Finally, improved EF ratios following ES-TIMP-1-CM transplantation were significantly 
(p<0.05) lower than sham in both TIMP-1 KO (81.37% ± 1.31%) and C57BL/6 (83.58% 
± 1.34%). TIMP-1 treatment data for the same parameter showed significance (p<0.05) 
only in C57BL/6 animals against sham, whereas TIMP-1 KO animals resumed normal 
ejection fraction.  
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Discussion 
 In the current study, we have examined the protective potential of ES-TIMP-1-
CM and TIMP-1 against adverse cardiac remodeling consecutive to MI in TIMP-1 KO 
mice and their controls (C57BL/6 mice).  Our cumulative data demonstrate ES-TIMP-1-
CM and TIMP-1 significantly: 1) blunt percent cardiac apoptosis, 2) decrease Caspase-
3 mediated cardiac myocyte cell death, 3) reduce interstitial and vascular fibrosis, 4) 
shrink infarct area and most importantly, 5) improve left ventricular contractile function in 
both C57BL/6 and TIMP-1 KO animals. Finally, we show evidence that TIMP-1 is 
sufficient to attenuate adverse remodeling to a similar extent between TIMP-1 KO mice 
and C57BL/6 mice.  
Cardiac apoptosis is considered the hallmark of cardiac ischemia. It is mediated 
by two distinct pathways; the extrinsic and the intrinsic pathways (20; 21). Extrinsic 
pathway is triggered by extracellular death ligands such as FAS, tumor necrosis factor 
(TNF)-α, or TRAIL, while intrinsic pathway is mediated through activation of Caspases 
activity (20; 21). TIMP-1 factor has been shown to blunt apoptosis in different cancer 
cell lines through modulation of the intrinsic pathway, however, not much is known 
about its anti-apoptotic role in the heart (9; 22). We have previously demonstrated that 
TIMP-1 released by ES cells inhibits apoptosis on cultured H9C2 cells (embryonic 
cardiac myoblasts) previously exposed to hydrogen peroxide (H2O2) (23).  
Furthermore, our next published data demonstrated ES-TIMP-1 cell delivery in the MI 
heart decreased Caspase-3 mediated apoptosis, however, whether this effect is 
mediated through TIMP-1 or other factors additionally released by ES-TIMP-1 cells was 
not clear (4). In the present study, we provide evidence that TIMP-1 alone is sufficient to 
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decrease overall cardiac apoptosis and specifically blunt Caspase-3 activity in cardiac 
myocytes following MI (Figures 11 and 12). Furthermore, TIMP-1 KO animals showed 
significantly higher Caspase-3 activity in cardiac myocytes compared to control mice 
following MI (Figure 12C). This further demonstrates the anti-apoptotic role of TIMP-1 in 
cardiac myocytes through inhibition of Caspase-3 activity.   
Cardiac myocyte apoptosis in the infarct and peri-infarct area precipitates 
collagen deposition in the interstitial and vascular spaces leading to stiffening of the left 
ventricle (9; 17; 22). TIMP-1 ability to blunt cardiac fibrosis through inhibition of MMPs is 
a well-documented fact (9; 17; 22). Additionally, previously published work has shown 
decreased fibrosis following ES-TIMP-1 cells transplantation in the MI heart (4). This 
decrease was associated with inhibition of endogenous MMP-9, a known promoter of 
collagen secretion and ECM degradation in the heart (4). However, it was unclear 
whether ES-TIMP-1-CM could provide a better outcome than TIMP-1 alone. Therefore, 
we measured interstitial and vascular fibrosis on TIMP-1 KO and C57BL/6 infarcted 
hearts following ESCM, ES-TIMP-1-CM and TIMP-1 treatments. Our data showed that 
although all treatments were efficient at blunting fibrosis (interstitial and vascular); the 
last two treatments provided the best outcome regardless of the strain. ES cells have 
been shown to release other anti-fibrotic factors such as hepatic growth factor (HGF) 
which has been linked to decreased fibrosis in lung alveolar epithelium (24). This 
explains, in part, the anti-fibrotic effect of our transplanted ESCM. However, TIMP-1 
seems to provide a stronger anti-fibrotic effect as demonstrated by the extent of fibrosis 
decrease we report following TIMP-1 treatment compared with any other combined 
factors released by ES cells.  
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Finally, we aimed at determining whether combined inhibition of apoptosis and 
fibrosis in the host myocardium contribute to decreased infarct size and improved 
cardiac function. Infarct size measurements are based on measurement of the infarcted 
area in tissue sections of the heart (25). Our data is in corroboration with previously 
published work, which demonstrated larger infarct area in TIMP-1 KO animals 
compared with their C57BL/6 counterparts two weeks following MI (7; 17; 22). 
Additionally, ESCM, ES-TIMP-1-CM and TIMP-1 treatments, all significantly reduced 
infarct size in both mice strains following MI; however, the extent of infarct resorption 
was more prominent in the last two groups (Figure 15). Reduction of infarct size upon 
TIMP-1 or MMP inhibitor transplantation in the infarcted myocardium has already been 
demonstrated (7; 17); however, we are first to report that ES-TIMP-1-CM will provide 
similar outcome. Furthermore, the infarct size measured in TIMP-1 KO and C57BL/6 
hearts were similar post TIMP-1 delivery even though the extent of infarction was bigger 
in the TIMP-1 depleted mice prior to treatment. The efficiency of infarct resorption in 
TIMP-1 KO animals treated with TIMP-1 exemplifies its importance in ECM regeneration 
and balance.  
Extent of infarct size area severely impacted left ventricular contractile ability as 
demonstrated by decreased fractional shortening and ejection fraction parameters 
measured following MI (Figure 16). Of note, the fractional data collected from TIMP-1 
KO animals were expectedly lower than the ones collected from C57BL/6 mice; 
however, ejection fraction was affected in the same way for both strains (Figure 16). 
The rather unpredicted EF data is in accordance with multiple previously published 
works demonstrating exacerbated left ventricular remodeling and decreased FS indices 
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in TIMP-1 KO mice following MI, with pseudo-normal to minimally affected ejection 
volumes (26). This was attributed to mitral regurgitation which accompanies acute MI in 
TIMP-1 KO mice and mitigates volumes measurements (26; 27). Nonetheless, ES-
TIMP-1-CM and TIMP-1 delivery significantly improved both FS and EF data in the 
infarcted heart of both strains. 
In conclusion, the present study compared the beneficial effect of direct 
intramyocardial delivery of TIMP-1 or ES-TIMP-1-CM in the MI setting. Our data 
revealed that both treatments significantly diminish Caspase-3 mediated cardiac 
apoptosis and fibrosis (interstitial and vascular) leading to significantly smaller infarct 
area and improved contractile function. Improved cardiac function is thought to be the 
result of limited cardiac myocytes loss and less collagen deposition within the host 
myocardium. Furthermore, we demonstrate that TIMP-1 factor alone is sufficient to 
significantly resorb cardiac remodeling in both TIMP-1 KO and control animals and 
resume similar cardiac function in both strains regardless of the extent of starting 
damage. However, future studies are necessary to identify the mechanisms by which 
TIMP-1 prevents adverse cardiac remodeling in the infarcted myocardium and how it 
overpasses any other anti-apoptotic anti-fibrotic mechanism provided by other ES cells 
released factors.  
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Figures  
 
Figure 11. ES-TIMP-1-CM and TIMP-1 blunt apoptosis in the Infarcted Myocardium 
of C57BL/6 and TIMP-1 KO mice.  TUNEL representative confocal photomicrographs 
demonstrating cardiac apoptosis are detailed in Figure 11A for C57BL/6 and Figure 11B 
for TIMP-1 KO mice. TUNEL positive nuclei are shown in red (a,d,g,j,and m), total nuclei 
stained blue with DAPI (b,e,h,k, and n) and merged TUNEL and DAPI images are 
depicted in (c,f,i,l and o). Histogram 11B depicts quantification of percent apoptotic 
nuclei against total DAPI for both C57BL/6 and TIMP-1 KO mice. Scale bar= 25µm. 
Data was collected from N=6 per group and 1 to 2 sections per animal.*p<0.05. vs 
Sham and #p<0.05 vs MI+CC. Brackets over each group means the given significance 
above it applies to both strains.  
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Figure 12. ES-TIMP-1-CM and TIMP-1 Blunt Caspase-3 Mediated Apoptosis in 
Cardiac Myocytes.  Figure 12A depicts confocal representative images obtained from 
MI-CC animals from C57BL/6 mice (a-f) and TIMP-1 KO (g-l) demonstrating apoptotic 
nuclei in red (a and g), Caspase-3 positive cells in yellow (b and h), sarcomeric α-actin 
positive cells in green (c and i), and total nuclei in blue (d and j). A merge of four 
stainings is depicted in white (e and k) and enlarged areas from e and k images are 
presented in f and l respectively.  Scale bar= 100µm. Histogram 12B represents 
quantitative analysis results of % apoptotic cardiac myocytes over total cardiac 
myocytes. Histogram 12B demonstrates Caspase-3 activity assay results for both 
strains and their respective treatments. Data was collected from N=5 per group and 1 to 
2 sections per animal.*p<0.05. vs Sham and #p<0.05 vs MI+CC. Brackets over each 
group means the given significance above it applies to both strains. 
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Figure 13. Reduced Interstitial Fibrosis Following ES-TIMP-1-CM and TIMP-1 
Transplantation in the Infarcted Myocardium.  Figure 13A depicts interstitial fibrosis 
(IF) representative images obtained from all study groups per strain; C57BL/6 mice (a-
e) and TIMP-1 KO animals (f-j). 20x magnification.  Histogram 13B shows quantitative 
analysis of measured interstitial fibrosis area in C57BL/6 and TIMP-1 KO animals. Data 
was collected from N=7 per group.*p<0.05. vs Sham and #p<0.05 vs MI+CC. Brackets 
over each group means the given significance above it applies to both strains. 
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Figure 14. Reduced Vascular Fibrosis Following ES-TIMP-1-CM and TIMP-1 
Transplantation in the Infarcted Myocardium.  Figure 14A depicts representative 
photomicrographs of vascular fibrosis obtained under a 20x objective of bright field 
Olympus microscope. C57BL/6 mice are in (a-e) and TIMP-1 KO animals are in (f-j).  
Figure 14B shows %vascular fibrosis per vascular area quantified on C57BL/6 and 
TIMP-1 KO animals. Data was collected from N=7 per group.*p<0.05. vs Sham and 
#p<0.05 vs MI+CC. Brackets over each group means the given significance above it 
applies to both strains. 
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Figure 15. Reduced Infarct Size Following ES-TIMP-1-CM and TIMP-1 
Transplantation in the Infarcted Myocardium.  Figure 15A shows representative 
whole-heart images depicting infarct size from both strains and all corresponding 
treatment groups under 2x magnification. Pink color represents healthy cardiac cells, 
blue areas represent fibrotic tissue (Infarct area). Histogram 15B shows quantification 
analysis of % infarct size in both C57BL/6 and TIMP-1 KO mice and their respective 
treatments. Data was collected from N=7 per group.*p<0.05. vs Sham and #p<0.05 vs 
MI+CC. Brackets over each group means the given significance above it applies to both 
strains. 
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Figure 16. Improved Heart Function Following ES-TIMP-1-CM and TIMP-1 
Transplantation in the Infarcted Myocardium.  Results of echocardiography analysis 
D14 post-surgery are presented in Figure 16. Table 16A summarizes quantitative data 
for % fractional shortening (FS) and ejection fraction (EF) parameters from all groups 
measured in both C57BL/6 and TIMP-1 KO mice. Histogram 16B represents FS% 
quantitative data in both stains and histogram 16C depicts %EF values obtained from 
both stains and all five treatment groups. (p<0.05, Figure 16). Data was collected from 
n=6-8 animals per group. *p<0.05 vs Sham, #p<0.05 vs MI+CC and $ p<0.05 vs 
MI+ESCM. Brackets over each group means the given significance above it applies to 
both strains. 
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CHAPTER FIVE: DISCUSSION 
Cell transplantation therapy for cardiac repair following MI has shown timid 
benefits given the limited survival and plasticity of transplanted cells (1; 2).  Therefore, 
boosting endogenous CSCs populations to promote cardiac regeneration is necessary 
to promote sufficient myocardium repair.  Tremendous efforts have been put in place to 
identify existent pools of endogenous CSCs (2; 3; 15; 21). Results from these studies 
demonstrate that following injury, CSCs proliferate and differentiate in an attempt to 
repair the damaged organ; however, the differentiation rate of these cells remains 
disproportionate as compared to the extent of cell loss (2; 3; 15; 21; 25). Therefore, 
identifying factors that can promote sufficient CSCs differentiation into cardiac myocyte, 
VSM and ECs to replace lost cells and regain pre-MI homeostasis is at the forefront of 
cardiac regenerative research.  
TIMP-1 is a protease inhibitor expressed in the ECM of many tissues including 
the myocardium to control MMPs-mediated aberrant collagen deposition (4; 5; 14). 
Additionally, it has been linked to multiple cellular processes including enhanced cell 
proliferation and inhibition of apoptosis (5; 19; 20; 26).  However, the ability of TIMP-1 to 
promote CSC proliferation and differentiation has not been established. In our 
previously published work, we engineered ES-TIMP-1 cells and transplanted them into 
the infarcted murine heart (14). Collected data demonstrated improved contractile 
function resulting at least in part from TIMP-1 enhancing transplanted ES cell 
engraftment, survival, and differentiation into cardiac myocytes (14). Therefore, we 
postulated that TIMP-1 released by ES-TIMP-1 cells may have further activated 
endogenous cardiac stem cells (CSCs) that express TIMP-1 receptor (CD63) leading to 
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indigenous cardiac regeneration therefore contributing to the reported improvement in 
cardiac function post MI injury.  
 In this regard, our first study (Chapter 2) aimed at identifying a sub-population of 
CSCs expressing CD63 and c-kit markers from isolated murine CSCs. We verified that 
TIMP-1 treatment enhances CD63+ve/c-kit+ve CSCs proliferation and differentiation into 
cardiac myocytes, VSM cells and ECs in vitro. Finally, we provided evidence that TIMP-
1 induces CD63+ve/c-kit+ve CSCs differentiation through enhancing cardiac genes 
(GATA-4, Mef2C and Nkx-2.5) expression.    
Our in vitro data established that 60% of isolated c-kit+ve CSCs were CD63+ve/c-
kit+ve and ES-TIMP-1-CM and TIMP-1 treatments significantly increased their 
proliferation rate. As previously mentioned in chapter 2, CD63 receptor is expressed in 
multiple cell types; however, we are first to report its expression by CSCs. Furthermore, 
enhanced CSCs proliferation mediated through TIMP-1/CD63 axis, demonstrated in this 
first study, is in accordance with previously published work on hMSCs which showed 
enhanced stem cell proliferation upon TIMP-1 binding CD63 on the cell surface (12). 
Next, we investigated whether TIMP-1 could promote significant CD63+ve/c-kit+ve 
CSC differentiation in vitro. Multiple factors released in the ES media have been shown 
to promote cardiac differentiation such as IGF1/2, bone morphogenetic protein-2 (BMP-
2), platelet-derived growth factor (PDGF) and VEGF (27; 28). However, the extent of 
cardiac differentiation is insufficient to restore pre-MI capacity (2; 21; 27; 28). Of note, 
TIMP-1 role in cell differentiation has been previously reported on germinal center B 
cells and  oligodendrocyte (23).  Its involvement in cardiac differentiation, however, has 
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not yet been established. In the present study, we are first to report that TIMP-1 
enhances cardiac differentiation by targeting a unique CSC population, CD63+ve/c-kit+ve.  
To further delineate the mechanism mediating CD63+ve/c-kit+ve CSC 
differentiation upon TIMP-1 treatment, we measured cardiac gene expression on 
isolated CSCs. GATA-4, Mef2C and Nkx-2.5 are cardiogenic factors expressed by stem 
cells undergoing cardiac differentiation (8-11; 31). Particularly, GATA-4 and Nkx-2.5 are 
indicative of myocyte differentiation while Mef2C is expressed in both cardiac myocyte 
and vascular differentiating cells (8-11; 31). Our collected data demonstrated that TIMP-
1 binding to its receptor expressed on CD63+ve/c-kit+ve CSCs surface triggers a 
downstream pathway which leads to enhanced cardiac genes expression resulting in 
CD63+ve/c-kit+ve CSCs differentiation. However, the intermediate signaling mechanism 
determining the differentiation fate of CSCs upon CD63 activation has not been the 
focus of this study and therefore remains to be elucidated.  
Taken together, our first study (Chapter 2) establishes the existence of a 
CD63+ve/c-kit+ve CSC population that is susceptible to proliferate and differentiate into 
cardiac myocytes and vascular cells in vitro upon treatment with TIMP-1. Furthermore, 
we show that TIMP-1/CD63 interaction leads to enhanced expression of GATA-4, 
Mef2C and Nkx-2.5 genes leading to enhanced cardiac differentiation. 
 We conclude our first study (Chapter 2) by highlighting the need for additional 
experiments aiming at identifying CD63+ve/c-kit+ve CSCs in vivo, their localization in 
respect to the infarct zone and their ability to migrate, proliferate and differentiate upon 
TIMP-1 transplantation. Additionally, identifying the molecular mechanisms promoting 
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their proliferation and differentiation could provide more insight on how these cells could 
be best taken advantage of in the clinical set up. 
In study 2 (Chapter 3), we aimed at addressing the above highlighted points by 
performing MI surgery on TIMP-1 KO and C57BL/6 mice followed by intramyocardial 
delivery of ESCM, ES-TIMP-1-CM or recombinant TIMP-1 protein. These three groups 
were done to emphasize the effect of TIMP-1 over any other factors released by stem 
cells present in the CM. We stipulated that TIMP-1 alone would be sufficient to activate 
CD63+ve/c-kit+ve CSCs and regenerate the damaged myocardium. Our collected data 
from study 2 demonstrate existence of CD63+ve/c-kit+ve CSCs population in the peri 
infarct heart. Futheremore, we provide evidence that intramyocardial delivery of ES-
TIMP-1-CM or TIMP-1 equivalently enhance CD63+ve/c-kit+ve CSCs proliferation and 
differentiation into cardiac myocytes, ECs and VSM cells, and promote additional CD63 
expression in the heart. Most importantly, this study for the first time demonstrates that 
endogenous TIMP-1 is necessary for CD63 expression on CD63+ve/c-kit+ve CSCs. This 
novel role of TIMP-1 was evidenced by the drastic reduction in CD63 expression 
resulting in decreased number of CD63+ve/c-kit+ve CSCs population in TIMP-1 KO 
animals compared to control mice. Moreover, exogenous delivery of TIMP-1 was 
sufficient to rebound CD63 expression and replenish CD63+ve/c-kit+ve CSCs pool in 
TIMP-1 KO animals.  
Next, we aimed at identifying the downstream mechanism governing CD63+ve/c-
kit+ve CSCs proliferation and differentiation upon TIMP-1 treatment. Stem cell 
differentiation is traditionally mediated through the canonical Wnt/β-catenin pathway; 
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however, our data from study 2 demonstrate CD63+ve/c-kit+ve activation bypasses Wnt 
but requires CD63 and β-catenin intermediates (6; 17; 18).  Activation of the non-
canonical CD63/β-catenin pathway is suggested by increased CD63, β-catenin and 
phospho-β-catenin expression in MI hearts treated with ES-TIMP-1-CM and TIMP-1 
when compared to non-treated animals. We therefore postulated that TIMP-1 treatment 
activates CD63 which induces dephosphorylation of Axin complex, preventing β-catenin 
ubiquitination and degradation. Released β-catenin then accumulates in the cytoplasm 
and is phosphorylated prior to nucleus translocation.  β-catenin thereafter induces 
cardiac gene expression and promotes cardiac proliferation and differentiation as 
previously reported (6; 17; 18). We additionally stipulated that endogenous TIMP-1 
activates CD63/β-catenin on CD63+ve/c-kit+ve CSCs promoting additional CD63 
expression. Our results are in accordance with multiple studies  demonstrating ES cells 
differentiate into cardiac cells through activation of β-catenin pathway and subsequent 
expression of cardiac genes, such as; Nkx2.5, GATA-4, Mef2C, β-myosin heavy chain 
(β-MHC) and cardiac troponin T (cTnT) (6; 9; 11; 31).   
In the present study, we choose to identify c-kit+ve CSCs population because of 
their prevalence in the heart. However, other CSCs exist such as side population (SP) 
cells, cardiac progenitor cells (CPCs), Sca-1+ve cells, cardio sphere cells and Isl1+ve cells 
which are less abundant and less characterized (2; 15; 21; 22; 25). It is therefore 
imperative to identify the relative contribution of CD63+ve CSCs that are not c-kit+ve in 
cardiac regeneration following MI.  
In conclusion for study 2, we provide evidence for the existence of a CSC 
population, CD63+ve/c-kit+ve, within the peri-infarct area of the murine heart. We show 
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that these cells can be triggered to differentiate into cardiac cells by exogenous delivery 
of TIMP-1 factor or ES-TIMP-1-CM. Finally, we demonstrate that CD63+ve/c-kit+ve CSCs 
activation is mediated through non-canonical CD63/β-catenin pathway.  
Besides the regenerative role identified in study 1 and 2, TIMP-1 is known to 
alleviate cardiac remodeling through inhibition of MMPs; however, not much is known 
about the molecular mechanism mediating this protective effect and whether other 
factors released in ESCM would provide a better protection (7; 16; 29). In study 3 
(Chapter 4), we compared the anti-cardiac remodeling effect of direct transplantation of 
TIMP-1 protein, ESCM, and ES-TIMP-1-CM in the MI heart of both C57BL/6 and TIMP-
1 KO mice. We hypothesized that parallel to enhancing cardiac proliferation and 
differentiation, TIMP-1 will surpass ESCM in blunting apoptosis and fibrosis in the MI 
heart. 
Our previously published data demonstrated ES-TIMP-1 cell delivery in the MI 
heart decreased Caspase-3 mediated apoptosis, however, whether this effect is 
mediated through TIMP-1 or other factors additionally released by ES-TIMP-1 cells was 
not clear . Within study 3, we provide evidence that TIMP-1 alone is sufficient to 
decrease overall cardiac apoptosis and specifically blunt Caspase-3 activity (an intrinsic 
mediator of apoptosis) in cardiac myocytes following MI. Furthermore, TIMP-1 KO 
animals showed significantly higher Caspase-3 activity in cardiac myocytes compared 
to control mice following MI which further establishes that TIMP-1 acts as a shield 
against cardiac myocytes apoptosis through inhibition of Caspase-3 activity.   
One of the hallmarks of cardiac remodeling is fibrosis, which results from 
collagen deposition in the interstitial and vascular spaces leading to stiffening of the left 
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ventricle, thereafter hindering its contractile capacity (7; 24; 29; 30). MMPs are well 
documented fibrosis mediators which function is predominantly controlled by TIMP-1(7; 
24; 29; 30). Our previously published work showed ES-TIMP-1 cells transplantation in 
the MI heart decreased overall interstitial and vascular fibrosis . However, it was unclear 
whether the anti-fibrotic effect was the result of TIMP-1 alone or other factors 
additionally released in ES-TIMP-1-CM. To address this question, we measured 
interstitial and vascular fibrosis on TIMP-1 KO and C57BL/6 infarcted hearts following 
ESCM, ES-TIMP-1-CM and TIMP-1 treatments. Our data showed that although all 
treatments were efficient at blunting fibrosis (interstitial and vascular); the last two 
treatments provided the best outcome regardless of the strain. Of note, hepatic growth 
factor (HGF), an ES cell-released factor present in their media and previously linked to 
decreased fibrosis in lung alveolar epithelium, might additionally be responsible for the 
deceased fibrosis reported in our ESCM hearts (13) . However, TIMP-1 seems to 
provide a stronger anti-fibrotic effect as demonstrated by the extent of fibrosis decrease 
we report following TIMP-1 treatment compared with any other combined factors 
released by ES cells.  
Finally, as part of study 3, we investigated the impact of TIMP-1 on infarct size 
measurements and left ventricular contractile function. Expectedly, our results were in 
accordance with previous work demonstrating larger infarct areas in TIMP-1 KO animals 
compared with their C57BL/6 counterparts two weeks following MI (7; 16). Moreover, 
infarct size measurements were significantly lower in ES-TIMP-1-CM and TIMP-1 
treatments as compared to either ESCM or non-treated animals. Furthermore, we are 
first to report that TIMP-1 anti-fibrotic effect is more efficient than any combined effects 
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from factors released by ES-TIMP-1 cells. Finally, we show that exogenous delivery of 
TIMP-1 is able to salvage equivalent amount of myocardium in TIMP-1 KO and 
C57BL/6 hearts even though the extent of infarction was bigger in TIMP-1 depleted 
mice prior to treatment.  
Functional data is greatly impacted by the extent of cardiac cell death and fibrotic 
tissue accumulation following MI. In fact, the larger the infarct size, the lower the ability 
of the ventricle to efficiently pump (7; 16). This in part explains why FS percent in TIMP-
1 KO animals were lower than C57BL/6 mice. Surprisingly though, EF data which reflect 
the amount of blood pumped out within every single contraction was similar in both 
strains. In other words, although infarct measurements and FS data were drastically 
lower in TIMP-1 KO infarcted hearts compared to C57BL/6 mice, volume measurements 
between both strains were apparently not affected.  To justify this observation, we 
postulated that mitral regurgitation which occurs in severely affected MI hearts and 
TIMP-1 KO animals for instance might have mitigated volume measurements in TIMP-1 
KO animals leading to pseudo normal EF numbers regardless to their dramatic left 
ventricular remodeling (7). Nonetheless, ES-TIMP-1-CM and TIMP-1 delivery 
significantly improved both FS and EF data in the infarcted heart of both strains. 
In conclusion, study 3 (Chapter 4) compared the beneficial effect of 
intramyocardial delivery of TIMP-1 or ES-TIMP-1-CM in the MI setting. Our data 
revealed that both treatments significantly diminish Caspase-3 mediated cardiac 
apoptosis, and reduce vascular and interstitial fibrosis leading to significantly smaller 
infarct sizes and improved contractile function in both control and TIMP-1 KO animals. 
Furthermore, we demonstrated that exogenous delivery of TIMP-1 factor can sufficiently 
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reduce cardiac remodeling in both TIMP-1 KO and control animals which resume similar 
cardiac function. In the current study, we stipulate that the anti-apoptotic and anti-fibrotic 
role of TIMP-1 in the heart is most likely mediated through CD63 receptor expressed on 
cardiac cells which most likely differentiated from CD63+ve/c-kit+ve CSCs previously 
identified in study 1 and 2. Nonetheless, future studies are warranted to verify this 
hypothesis.   
Overall, study 1, 2 and 3 demonstrate that CD63+ve/c-kit+ve cells are a novel CSC 
population present in the peri-infarct area of the heart. When treated with TIMP-1 both 
in vitro and in vivo, CD63+ve/c-kit+ve CSCs showed 1) increased proliferation compared 
to control cells, 2) enhanced CD63 expression, 3) significantly improved cardiac 
myocyte, VSM cell, and EC differentiation, 4) increased cardiac gene (GATA-4, Mef2C, 
and Nkx-2.5) expression, 5) CD63+ve/c-kit+ve  differentiation is mediated through 
CD63/β-catenin pathway, and 6) TIMP-1 inhibits apoptosis and fibrosis and improves 
contractile function following myocardial transplantation. Our data provided in the 3 
studies demonstrate for the first time the multi-faceted role of TIMP-1. This molecule 
has a strong regenerative potential through activation of endogenous CD63+ve/c-kit+ve 
CSCs while alleviating adverse cardiac remodeling consecutive to MI, therefore opening 
a new era for cardiac  regeneration research. 
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